centre of excellence

treatable traits

Annual Report 2024-2025

.

Contents

Message from the director 2
Centre at a glance 3
Who are we? 3
Why are we doing this? 3
Impact Overview 5
New Knowledge: Research Themes 7
Highlighted Research 8
Oral Corticosteroid Stewardship 8
Vocal cord dysfunction programme of work 9
Physical activity programme of research 10
Severe refractory asthma: Remission 11
Asthma in pregnancy 12
Translation Resources 13
Overview 13
ILO/VCD Toolkit 14
Knowledge Exchange & Training 15
Annual Research Meeting 2025 15
Thoracic Society of Australia and New Zealand Education Hub 17
..... 18
TSANZASM 2025 19
Journal Club 20
Webinars 21
Social Media 21
Grants, Award and Achievement Highlights 22
Consumer Engagement 23
Optimising Asthma Community Event 23
Smarter OCS Collaboration with Asthma Australia 24
Collaboration 25
International visitor highlights 25
Our People 26
Directors 26

Chief Investigators 26
Associate Investigators 26
Research Fellows 26
Research and Education Affiliates 27
Research Higher Degree Students 27
Centre Staff 27
Centre Executive 27
Our Publications 2024-2025 28
Our partners 51
Contacts 51

Message from the director

As we move through another busy and productive period for our CRE in Treatable Traits, it is a pleasure to reflect on the momentum we have built across our community and the impact of our work.

Across the Centre, we continue to embed the treatable traits approach into research and translate to practice, driving precision, improving outcomes, and keeping people at the centre of their care. From advances in mechanistic and clinical research, to meaningful engagement with clinicians, consumers, and policy partners, our work is increasingly translating beyond traditional academic boundaries and into real-world practice.

This annual report also marks an important moment of reflection, as the CRE in Treatable Traits approaches the conclusion of its formal funding period (April 2026). While endings are always bittersweet, this moment provides an opportunity to recognise just how much has been achieved. Together, we have built a nationally and internationally recognised research programme, fostered a collaborative and inclusive research culture, and supported the development of emerging research leaders in airway diseases who will carry this work forward.

I am immensely proud of the people who have shaped the CRE, our investigators, early- and mid-career researchers, students, professional staff, and partners. Your leadership, generosity, and shared commitment to impact have been the foundation of our success. Importantly, the conclusion of the CRE does not mark an end to the work, the relationships, or the vision. The principles of treatable traits, and the community we have built around them, will continue to inform and influence research, clinical practice, and policy well beyond the life of the Centre.

Thank you to everyone who has contributed to the life of the CRE; through research, education, advocacy, and support of one another. I hope you enjoy this edition of the annual report and take pride in what we have accomplished together, and in the legacy that will endure.

Wishing you a safe, harmonious and restorative festive season.

With best wishes,

Vanessa

Centre at a glance

Who are we?

We are a consortium of world-renowned clinicians, researchers and peak respiratory organisations who are collaborating to improve healthcare outcomes for people with airway diseases. We are a team that includes 20 investigators, 22 research fellows, 9 research and education affiliates and 10 research higher degree candidates.

Our mission is to revolutionise the management of chronic airway disease by testing and implementing "Treatable Traits" approaches - A new paradigm for personalised medicine.

Why are we doing this?

The crisis point is now for people with lung disease. In Australia, at least one person dies every day from asthma, and 19 people die per day from COPD. Additionally, asthma deaths are on the rise in developed countries.

The improvements in asthma outcomes that were achieved in the late 20th Century are being lost. This is extremely alarming since asthma and COPD are treatable diseases.

A feature of asthma and COPD is the variability or heterogeneity of presentation. Heterogeneity assumes that within and between individuals, the clinical, biological, and functional presentation of diseases vary.

While current management approaches have led to significant improvements in outcomes, they are unable to sufficiently address this heterogeneity. Personalised medicine is a novel approach to disease management that is delivering considerable improvements in disease-related outcomes and health-related quality of life in many areas of medicine, including cancer and other respiratory diseases. Personalised medicine accounts for heterogeneity by targeting the needs of individuals based on distinguishing genetic, biological, phenotypic, or psychological characteristics.

The variability of clinical presentation and treatment response is recognised among clinicians who manage chronic lung diseases; however, this variability is not routinely addressed.

A solution to address the excessive disease burden faced by people with asthma and COPD is a personalised-medicine-based strategy called-

"Treatable Traits".

Our Centre aims to generate new knowledge in the field of Treatable Traits, translate this new knowledge into practice using novel models of care, train the next generation of researchers, and collaborate and grow our national and international networks.



Impact Overview



Since its establishment, the Centre has demonstrated outstanding leadership in advancing research, education, and translation within respiratory health. Our collective achievements include the publication of 515 peer-reviewed articles, generating more than 11,835 citations and significantly contributing to the global evidence base for precision and treatable traits–based care. The Centre's research excellence has been underpinned by over $24 million in competitive funding, reflecting the confidence of national and international funding bodies in the quality, relevance, and impact of our work.

In translation and impact, the Centre has developed a suite of practical resources, including 50 infographics, multiple clinical toolkits (Asthma in Pregnancy, Severe Asthma, and ILO/VCD), the Treatable Traits Website, and influential position papers through the Thoracic Society of Australia and New Zealand (TSANZ). These outputs, along with our successful advocacy through Pharmaceutical Benefits Advisory Committee (PBAC) submissions, the Smarter OCS Use partnership with Asthma Australia, and a government submission on Long COVID, demonstrate our enduring commitment to improving patient outcomes, shaping policy, and advancing the integration of evidence into clinical care.

Over this period, the Centre has delivered a comprehensive programme of training and educational initiatives, including 20 webinars (with more than 6,000 engagements) and 27 journal clubs (over 500 engagements), alongside participation in national forums such as the TSANZ Education Hub (2024–2025), collectively reaching more than 700 clinicians, researchers, and scientists. Our

Annual Research Meetings remain a flagship event, driving collaboration and showcasing innovation across the respiratory research community.

Collaboration and engagement remain central to the Centre's success. We have built strong partnerships with leading academic institutions, professional societies, government agencies, and consumer organisations across Australia and internationally. The Centre has hosted visiting scholars from Denmark, England, the United Kingdom, Brazil, Japan, and China, fostering knowledge exchange and strengthening global collaboration despite the challenges of the pandemic. Through these partnerships and our sustained engagement with the clinical, research, and consumer communities, the Centre continues to amplify its reach, accelerate innovation, and transform the landscape of chronic respiratory disease management both nationally and globally.

New Knowledge: Research Themes

The Centre has two overarching research themes which will generate new knowledge, translate it to practice and build a new generation of researchers in this area.

The Centre has made some major progress within the past year, generating new knowledge across our research priorities.

With our first theme focused on developing the knowledge of the Treatable Traits approach using clinical trials, we have been successful in receiving category one funding, completed two trials and have commenced four randomised controlled clinical trials.

These studies align with our Centre's priority of reducing the side effects of treatment, gaining an understanding of breathlessness in people with asthma, as well as determining an optimal model of care for the management of asthma. Our asthma in pregnancy research programme continues to make major gains in the past year including a significant funding boost.

Our Centre members have also successfully received more than $7 million to further our research studies over the next few years! These grants will go towards studies aimed at:

- Implementing a treatable traits approach to optimise care of high-risk chronic respiratory disease (the TAPPET trial)
- Treatable Traits in Asthma in pregnancy, patient, and practitioner priorities of care
- Developing a breathlessness intervention, a digital style approach to the management of breathlessness and physical activity
- Co-designing effective treatment models for Aboriginal and Torres Strait Islander women with asthma during pregnancy
- Gaining an understanding of how different types of treatment can achieve the complete removal of asthma symptoms and attacks, called treatment-induced asthma remission

Highlighted Research

Oral Corticosteroid Stewardship

Oral corticosteroids are associated with significant adverse effects and increased morbidity, however, they are a cornerstone for the management of acute asthma attacks and some people require regular maintenance of oral corticosteroids. The use of oral corticosteroids is high in people with asthma. Based on the research from our investigators in 2019 it was identified that approximately 25% of people with severe asthma take oral corticosteroids every day. A more recent audit of the PBS data found that of 51% of people prescribed medication for asthma were prescribed oral corticosteroids, and of those 27.9% reached the cumulative toxic dose of at least 1000mgs over a five-year period. To address the significant burden faced by people with asthma in relation to these toxic treatments we have developed a body of work to develop and implement oral corticosteroid stewardship.



Vocal cord dysfunction programme of work



Significant progress has been made in improving knowledge and care around Vocal Cord Dysfunction as part of Theme 2. At the commencement of the Centre, a key issue was that diagnostic definitions were not well agreed upon. This was the catalyst for a Centre-lead international Delphi which resulted in the first internationally agreed upon diagnostic definition for the disorder. A Centre convened international roundtable has enhanced dialogue and collaboration, with agreement on new directions for the field, including the importance of phenotypes.

Further work has provided important data on associations and treatments, and for the first time patient experience has been described.

Translating knowledge into action has been a key focus. Dr Paul Leong's INNOVATE award has provided resources, helping scale VCD MDTs in Australia & New Zealand. Finally, a dedicated VCD/ILO online toolkit has been developed and launched! You can find it here https://ilovcdtoolkit.org/

ILO/VCD Snapshot

12 Publications	International Roundtable	International Consensus Delphi	ILO/VCD Toolkit
12 peer reviewed journal articles	Convened an international roundtable Enhanced dialogue and collaboration	The first internationally agreed upon diagnostic definition for the disorder	Dedicated VCD/ILO online has been launched!



The Physical Activity Research Programme has been a standout success, exemplifying the Centre's fourth core objective: Collaboration. The programme has fostered meaningful international partnerships through a PhD exchange initiative with researchers in Denmark and Brazil, while also establishing and strengthening key collaborations within the UK research community. To date, the programme has secured over $7 million in research funding, produced 12 peer-reviewed publications, and made a significant impact on both policy and clinical practice, including guidelines for COVID-19 and exercise, the Australian 24-hour Movement Guidelines for Children (5-12 years) and Young People (13- 17 years), and an International position paper through the European Academy of Allergy and Immunology on Exercise Recommendations for Asthma Management. Our CIs are also leading the update of the Australia and New Zealand guideline for Pulmonary Rehabilitation for Adults with Chronic Respiratory Disease.

Severe refractory asthma: Remission Focus

The Severe Asthma Research team has made major strides toward the objective of new knowledge in advancing the concept of asthma remission. Asthma remission is now a viable clinical goal. Through a series of groundbreaking studies, the team has demonstrated that long-term treatment with azithromycin can induce clinical remission in up to 50% of patients with moderate to severe asthma, regardless of inflammatory subtype. In addition, real-world evidence from national registries has shown that biologic therapies such as mepolizumab and omalizumab can achieve remission in up to 29% of patients with severe asthma after 12 months of treatment. These findings are influencing international treatment guidelines and contributing to a shift in clinical practice. The team has also played a leading role in defining the criteria for asthma remission and advocating for its adoption as a formal treatment target, supported by ongoing work through the FUTURE programme and other collaborative initiatives. The work has resulted in more than 12 peer-review publications around the topic of asthma remission and more than $4 million in competitive funding, as well as a field-defining roundtable and a visiting fellow from Japan.

New Knowledge

More than 10 peer review publications

Influence

A transnational roundtable

Funding

More than $4 million in competitive research funding

Capacity Development

International Fellow
PhD candidate

Asthma in pregnancy

Over the past five years, the Asthma in Pregnancy team has made substantial advances in understanding and managing asthma through a treatable traits framework for pregnant women. The team has published 22 peer-reviewed papers, including six invited reviews and the landmark *Breathing for Life Trial*- the largest randomised controlled trial in the field to date.

This body of work has significantly shaped international understanding of asthma management during pregnancy and its implications for maternal and infant outcomes. Over $7.3 million in competitive funding has been secured to support this programme of research, including three major Medical Research Future Fund (MRFF) grants. These projects are examining treatable traits in pregnant women across ten clinical sites in New South Wales and Victoria, and co-designing culturally safe, community-led models of asthma care for Aboriginal and Torres Strait Islander women.

Additional funding from partners such as the John Hunter Hospital Charitable Trust, ACT Government, and the College of Health, Medicine and Wellbeing supports projects investigating sleep apnoea, biomarker-guided asthma management, and health promotion initiatives for women and families. Collectively, this research programme continues to deliver internationally recognised outputs and tangible improvements in respiratory care during pregnancy.



Translation Resources

Overview

Our Centre investigators have continued to lead the development of impactful translational resources that bridge research, clinical practice, and policy to improve respiratory health outcomes. To date, we have produced 50 infographics that translate complex research findings into accessible, practical tools for clinicians and consumers. The Treatable Traits Website remains a central hub for knowledge translation, hosting toolkits, infographics, and implementation resources for multidisciplinary teams.

This year saw the update of the Severe Asthma Toolkit, along with the release of the ILO/VCD toolkit. The Centre also contributed to several Pharmaceutical Benefits Advisory Committee (PBAC) submissions aimed at improving access to medications and reducing oral corticosteroid (OCS) use.

The Centre's ongoing OCS Stewardship Programme launched in 2021 has included a TSANZ Position Paper and infographic, a TSANZ ASM symposium, a patient panel at the Education Hub aimed to understand OCS use from a consumer perspective, a Medicine Today article with Professors Bardin, Politis, and Blakey, and a podcast interview featuring Professor John Blakey and Professor Vanessa McDonald.

The team has also published an impact case study on the Centre's website and petitioned the PBAC (in collaboration with TSANZ, Asthma Australia, CRE-TT, and CRE-SA) to reduce OCS use, successfully removing the OCS requirement for mepolizumab prescriptions. This work has been further strengthened through the successful INNOVATE funding round, an OCS stewardship survey with Asthma Australia, multiple local education sessions, and a clinician-focused OCS stewardship webinar in May 2025. In partnership with Asthma Australia, the Centre has also supported the Smarter OCS Use campaign, promoting safer and more informed corticosteroid use through public and professional education

Additional resources include the Asthma in Pregnancy Toolkit, a Lung Learning Framework submission for OCS, and a government submission on Long COVID. Collectively, these translational initiatives highlight our leadership in advancing evidence-based practice, driving policy change, and enhancing capacity across the respiratory healthcare landscape.

ILO/VCD Toolkit

A major achievement this year was the launch of the Inducible Laryngeal Obstruction/Vocal Cord Dysfunction (ILO/VCD) Toolkit, unveiled at the Thoracic Society of Australia and New Zealand Annual Scientific Meeting (TSANZASM) to a standing-room-only audience during a dedicated symposium. Developed to support clinicians in the recognition, diagnosis, and management of ILO/VCD, the toolkit has generated significant national and international attention. Since its release in late March, it has received more than 5,000 views from users across Australia, the United States, the United Kingdom, China, and beyond.

The toolkit has also been featured on ABC Radio National's *Health Report* with Norman Swan, as well as through other local media outlets, amplifying its reach and impact. This resource represents a key translational achievement for the Centre, providing multidisciplinary teams with practical, evidence-based guidance to improve patient outcomes in complex airway disorders https://Ilovcdtoolkit.org/

Knowledge Exchange & Training

The Centre has led a comprehensive suite of training and educational initiatives designed to build capacity and foster collaboration among multidisciplinary respiratory clinicians, researchers, policy advisors, and scientists. These initiatives include face-to-face national education meetings, such as the Thoracic Society of Australia and New Zealand (TSANZ) Education Hub (2022, 2024, 2025), where investigators contributed as part of the organising committee, and selected plenary symposia at transnational meetings including the TSANZ Annual Scientific Meetings (2022–2026).

The Centre's INNOVATE Programme further strengthens translational impact and training by supporting the development of EMCRs. Through successful funding rounds, the INNOVATE Programme has created opportunities for clinician–researcher collaboration, embedding research into real-world clinical practice and accelerating the adoption of evidence-based approaches to respiratory care, with $150K in funds awarded. Complementing this, the Centre's mentoring programmes provide tailored support for early and mid-career researchers, clinicians, and higher degree students fostering skill development, leadership, and career progression across disciplines. These initiatives have been instrumental in building a skilled, confident, and connected research workforce ready to address the future challenges of respiratory health.

In addition, the Centre has delivered an ongoing programme of webinars, annual research meetings, postgraduate course sessions, journal clubs, and focused research development meetings. Collectively, these educational activities have attracted more than 7,000 engagements, strengthening national and international collaboration, supporting professional development across the respiratory sector, and advancing the translation of research into clinical and policy impact.

Annual Research Meeting 2025

The 2025 Annual Research Meeting was a highlight of the Centre's calendar, bringing together clinicians, researchers, and advocacy partners to share innovation, foster collaboration, and celebrate progress in respiratory health research. The two-day program featured dynamic sessions on oral corticosteroid stewardship, digital health and practice change, and modifiable treatable traits, highlighting both emerging and established research excellence. A key feature of the meeting was the DARE (Developing Academic Research Excellence) Talks, a brain child of Professor McDonald's these TED-style presentations encourage speakers talk on topics they are passionate about, blending evidence, storytelling, and humour to inspire and build research capacity.

Other highlights included new insights into asthma remission, dysfunctional breathing, bronchiectasis, and long COVID, as well as an engaging panel on career progression pathways for early- and mid-career researchers. The meeting concluded with robust discussion on the application of treatable traits across a range of chronic respiratory conditions, reinforcing the Centre's commitment to collaboration, capacity building, and translation of research into practice and policy impact.

Thoracic Society of Australia and New Zealand Education Hub

The Centre played a leading role in the Thoracic Society of Australia and New Zealand (TSANZ) Education Hub, held in consecutive years in 2024 and 2025. The conference chair was our own Professor Vanessa McDonald, and our members served as committee members, speakers and session chairs. The Centre helped to shape and deliver two highly successful programmes that brought together experts across the respiratory community.

Collectively, the two events held in Melbourne, and then Sydney, attracted more than 700 clinicians, researchers, and scientists, providing an interactive platform for professional development, knowledge exchange, and collaboration. The Centre's leadership in these national education initiatives reflects its commitment to building capacity and strengthening the translation of research into clinical and policy impact across the respiratory health sector.

Centre Chief Investigators Professor Vanessa McDonald and Professor Anne Holland with the Victoria Health Minister at the TSANZ Education Hub in Melbourne.

TSANZ

TSANZ
Welcome



Overview

TSANZASM 2025

The Thoracic Society of Australia and New Zealand (TSANZ) Annual Scientific Meeting was held in Adelaide, bringing together more than 1,000 delegates from across Australia and New Zealand. The Centre had a strong presence at the meeting, with over 20 delegates in attendance who presented, chaired sessions, and contributed to symposia, showcasing the Centre's leadership and expertise across the respiratory research community.

A major highlight was the invited symposium that launched the Inducible Laryngeal Obstruction/Vocal Cord Dysfunction (ILO/VCD) Toolkit, aimed at improving understanding and management of ILO/VCD. The session attracted a standing-room-only audience and generated significant discussion and engagement.

The meeting provided an exceptional platform for the Centre to share new knowledge, strengthen collaborations, and further its mission to advance evidence-based, patient-centred care in respiratory health. It also marked the completion of Professor Anne Holland's tenure as TSANZ President, before fittingly concluding with some impressive moves on the dance floor at the Gala Dinner.

Journal Club

The Centre has hosted 27 journal clubs to date, fostering critical discussion, collaboration, and ongoing professional development among clinicians, researchers, and students. These sessions provide a structured yet interactive forum to appraise emerging evidence, explore methodological approaches, and translate research findings into clinical and policy contexts. With more than 500 engagements across these sessions, the journal clubs have become a cornerstone of the Centre's research culture supporting capacity building, encouraging multidisciplinary dialogue, and strengthening the integration of evidence-based practice across the respiratory health community.

Recent papers presented were:

- Greenhouse gas emissions associated with suboptimal asthma care in the UK: the SABINA healthCARe-Based envirONmental cost of treatment-John Harrington
- Composition and Variation of the Human Milk Microbiota Are Influenced by Maternal and Early-Life Factors, Moossavi et al., Cell Host & Microbe- Dr Megan Jensen.
- NOTUS trial: Dupilumab for COPD with Blood Eosinophil Evidence of Type 2 Inflammation. Bhatt SP, et al. N Engl J Med. 2024- Dr Arwel Jones
- BICS trial: Bisoprolol in Patients With Chronic Obstructive Pulmonary Disease at High Risk of Exacerbation: The BICS Randomized Clinical Trial. Devereux G, et al. JAMA. 2024 – Dr. Arwel Jones.
- Lung-function trajectories: relevance and implementation in clinical practice. Melen et al., Lanc Resp Med 2024- Ms Brooke Bailey.

Webinars

Over the past five years, the Centre has delivered 20 high-impact webinars focused on clinician and researcher development. Topics have spanned key areas of clinical and research excellence, including OCS stewardship, breathlessness, asthma in pregnancy, severe asthma management, long COVID care, implementation science, and impact assessment. Several of these sessions were co-led with our partners from Asthma Australia and the Thoracic Society of Australia and New Zealand, strengthening collaboration and sector-wide knowledge exchange. Collectively, these webinars have reached more than 6,000 participants across Australia and internationally, supporting knowledge translation and capacity building across diverse professional audiences. They have since been incorporated into our broader webinar suite of a further 22 sessions, which have now amassed over 20,000 views, reflecting strong and sustained engagement with our educational and translational research initiatives.

Social Media

Did you know we have a LinkedIn page? You can follow up to catch up with what we have been up to.

https://www.linkedin.com/company/99404655/admin/feed/posts/

Grants, Award and Achievement Highlights

We celebrate the achievements and prestigious accolades of our centre investigators and members:

Professor Anne Holland: NHMRC Investigator Grant *Advancing non-drug treatments to improve lung health Monash University $2,954,575*

Professor Vanessa McDonald awarded the prestigious Lung Legend Award by the Lung Foundation Australia

Professor Anne Holland- NHMRC 10 of the Best

Professor Vanessa Murphy- HMRI Mid-Career Researcher of the Year 2024

At the Thoracic Society of Australia and New Zealand Annual Research Meeting 2024 and 2025:

Dr Arwel Jones received the Moderna Research Award for Lung Health-Immunisation for his project "Exercising as an adjuvant to vaccination in COPD.

Dr Dennis Thomas received the Janet Elder Travel Award: Mid-career researcher for his abstract "Azithromycin induced asthma remission: Secondary analysis of a placebo-controlled- RCT".

Dr Megan Jensen received the Thoracic Society of Australia and New Zealand Chiesi Advancing Women in Respiratory Health.

Ms Paola Urroz-Guerrero received a Thoracic Society of Australia and New Zealand travel grant.

Brooke Bailey Lung Foundation Australia David Serisier Memorial Award for Translational Research in Bronchiectasis

Dr Hayley Lewthwaite TSANZ SIG Orals Award: Symptom Support & Palliative Care

Dr Angela Burge TSANZ Past Presidents Scholarship Award

Consumer Engagement

Optimising Asthma Community Event

The Centre, in conjunction with HMRI hosted a community engagement event "Optimising Asthma Community Forum" in Newcastle.

The month of May marked lung health awareness month and it was an honour to invite members of the community to hear directly from Centre members. Despite torrential downpour in Newcastle, we reached 60 people face to face and online with 40 naive to our research programme. We heard short talks from both Professor Vanessa McDonald and Dr Rifat Chaudry followed by an expert panel with open discussion, which included Vanessa, Rifat and Professor Vanessa Murphy, Mr John Harrington and Professor Peter Gibson.

It was a successful evening with positive feedback and a great opportunity to give back to the community members.

Smarter OCS Collaboration with Asthma Australia

In 2025, the Centre partnered with Asthma Australia to launch the Smarter OCS (Oral Corticosteroid) Use Campaign on World Asthma Day, reinforcing a shared commitment to improving the safe and effective use of corticosteroids in asthma management. This national collaboration aims to raise awareness among both clinicians and consumers about the potential harms of inappropriate OCS use, promote evidence-based prescribing, and support people with asthma to make informed decisions about their care. The campaign features accessible educational materials, patient stories, and clinician resources co-developed by the Centre and Asthma Australia to drive behaviour change and improve outcomes. By combining research expertise with consumer advocacy, this partnership exemplifies the Centre's translational impact transforming evidence into action to reduce OCS reliance and enhance the quality and safety of asthma care across Australia: https://asthma.org.au/smarter-oral-steroids/

Collaboration

Despite the Centre's establishment coinciding with the global COVID-19 pandemic and the associated travel restrictions during its first two years, international engagement has been remarkably strong. The Centre has welcomed13 visiting researchers and collaborators from Denmark, Hong Kong, the United Kingdom, Brazil, Japan, and China, reflecting its growing global reputation for excellence in respiratory research and innovation. These visits have fostered new partnerships, strengthened cross-country collaborations, and facilitated the exchange of ideas, skills, and methodologies. The sustained international interest in the Centre's work underscores its leadership in advancing treatable traits, precision care, and translational research on the world stage.

International visitor highlights

Professor Vibeke Backer joined us in 2025, with two visiting PhD students from Denmark. During her visit, Vibeke gave a webinar updating us on "Chronic rhinosinusitis with nasal polyps registry: Two year follow-up", which detailed the success of biological therapies for nasal polyps. The two visiting PhD students, Dr Jen Tidemandsen and Christiane Haase visited the Centre for 6 weeks, and we were delighted that they shared their research around management and experience of nasal polyps with us.

We were also fortunate to be visited by Professor Janelle Yorke and Assistant Professor Naomi Takemura, as part of their visit they presented a seminar on 'Symptom experience from United Kingdom to Hong Kong: dynamic monitoring and management'. This innovative seminar generated a lot of fruitful discussion around the future of Treatable Traits



Our People

Directors

Professor Vanessa McDonald
Professor Peter Gibson

Chief Investigators

Professor Richard Beasley
Professor Andrew Searles
Associate Professor Vanessa Murphy
Professor Philip Bardin
Professor Anne Holland
Professor Ian Pavord
Professor John Upham
Professor Michael Peek

Associate Investigators

Professor Alvar Agusti
Dr James Fingelton
Associate Professor Anne Vertigan
Professor Luke Wolfenden
Professor Mark Hew
Professor Peter Wark
Associate Professor Celso Carvalho
Mr Gregory Archbold
Mr Anthony Flynn- Asthma Australia
Dr Hayley See- Thoracic Society of Australia and New Zealand

Research Fellows

Dr Rebecca McLoughlin (University of Newcastle, NSW, Australia)
Dr Paul Leong (Monash Health, VIC, Australia)
Dr Dennis Thomas (University of Newcastle, NSW, Australia)
Dr Hayley Lewthwaite (University of Newcastle, NSW, Australia)
Dr Tesfalidet Beyene (University of Newcastle, NSW, Australia)
Dr Janine Mahony (LaTrobe University, Melbourne, VIC, Australia)
Dr Arwel Jones (Monash Health, Melbourne, VIC, Australia)
Dr Alex Gordon (University of Newcastle, NSW, Australia)
Dr Christian Osadnik (Monash Health, Melbourne, VIC, Australia)
Dr Eve Denton (The Alfred, Melbourne, VIC, Australia)
Ms Janet Bondarenko (The Alfred, Melbourne, VIC, Australia)
Dr Jenny Sparks (MRINZ, Wellington, New Zealand)
Dr Joy Lee (The Alfred, Melbourne, VIC, Australia)
Dr Eleanor Majellano (University of Newcastle, NSW, Australia)
Dr Donna-Marie Palakiko (University of Hawaii, Manoa, USA)
Dr Elissa Elvidge (University of Newcastle, NSW, Australia)

Dr Annelies Robijn (University of Newcastle, NSW, Australia)
Mrs Jordan Jeffery (HNELHD John Hunter Hospital, Newcastle, NSW, Australia)
Dr Clare Tideman (Hunter New England Area Health)
Dr Megan Jensen (University of Newcastle, NSW, Australia)
Dr Yuto Hamada (University of Newcastle, NSW, Australia)

Research and Education Affiliates

Emeritus Professor Jennifer Oates (La Trobe University, Melbourne, VIC, Australia)
Ms Adriana Avram (Monash Health, Melbourne, VIC, Australia)
Dr Debbie Phyland (Monash University, Melbourne, VIC, Australia)
Dr Joo Koh (Monash Health, Melbourne, VIC, Australia)
Mr Laurance Ruane (Monash Health, Melbourne, VIC, Australia)
Ms Elizabeth Leahy (Monash Health, Melbourne, VIC, Australia)
Mr Malcolm Baxter (Monash Health, Melbourne, VIC, Australia)
A/Professor Woo-Jung Song (University of Ulsan, Seoul, Korea)
Dr Bronwyn Brew (University of Newcastle, NSW, Australia)

Research Higher Degree Students

Ms Paola Urroz (University of Newcastle, NSW, Australia)
Dr Esha Joshi (University of Newcastle, NSW, Australia)

Centre Staff

Dr Vanessa Clark – Centre Research Manager

Centre Executive

The Centre executive is comprised of our two directors, Professor Vanessa McDonald & Professor Peter Gibson, and the Centre Research Manager Dr Vanessa Clark.

Our Publications 2024-2025

- Harvey ES, Hamada Y, Hiles SA, Langton D, Thomas D, McDonald VM, Bardin P, Peters M, Reynolds PN, Upham JW, Blakey J, Bowler S, Chien J, Chung LP, Farah CS, Gillman A, Harrington J, Hew M, Jenkins C, Katelaris CH, Katsoulotos GP, Kritikos V, Lee J, Radhakrishna N, Sivakumaran P, Wark PAB, Gibson PG, 'Mepolizumab treatment and reduced oral corticosteroid exposure improves symptoms of depression and anxiety in severe eosinophilic asthma: data from the Australian Mepolizumab Registry', Respiratory Medicine. 2025.
- Anderson GP, Flynn A, Bardin PG, Blakey JD, Dharmage SC, Foster P, Gibson PG, Jaffe A, James A, Jenkins CR, Sivamalai S, Sly PD, Marks GB, McDonald VM, Wetttenhall J, 'The CURE Asthma roadmap', Medical Journal of Australia. 2025.
- Farinha I, Gibson PG, McDonald VM, Heaney LG, 'Treatable Traits as a Pathway to Remission in Asthma', Journal of Allergy and Clinical Immunology in Practice. 2025.
- Peters S, Francis JJ, Wolfenden L, Gibson PG, McDonald VM, Yang IA, Rankin NM, Thompson B, 'Accelerating the uptake of evidence-based respiratory medicine through implementation science', Lancet Respiratory Medicine. 2025.
- Flynn A, Edmondson W, James A, Lodge C, McDonald VM, Jenkins CR, Blakey J, Anderson GP, 'CURE Asthma: a unique opportunity for Australia', Medical Journal of Australia. 2025.
- Zhuang A, Thomas D, Lodge C, Bourke JE, Upham JW, McDonald VM, Wark PAB, Anderson GP, 'Finding cures for asthma: new paradigms for drug discovery and therapy', Medical Journal of Australia. 2025.
- Wu W, McDonald VM, Wang G, Gibson PG, 'The value of treatable traits across the spectrum of adult asthma severity.' Chinese medical journal pulmonary and critical care medicine. 2025.
- McDonald VM, 'Anti-inflammatory reliever therapy for children with asthma', Lancet, 406, 1444-1445. 2025.
- Thomas D, McDonald VM, Gibson PG, Kim RY, 'Defining “cure” for the asthmas', Medical Journal of Australia. 2025.
- Wang Y, Li Y, Hu Y, Lewthwaite H, Zhu B, Liao K, Li M, Dai Y, Takemura N, McDonald VM, Yorke J, 'Effectiveness of Mindfulness-Based Interventions on Breathlessness in Lung Cancer: A Meta-Analysis.', Journal of pain and symptom management. 2025.
- Oliveira JM, Urroz Guerrero PD, Lewthwaite H, Clark VL, Furlanetto KC, Gibson PG, McDonald VM, 'Safety of the 6-min walk test in adults with severe asthma', Respiratory Medicine. 2025.
- AW Jones, VM McDonald, RF McLoughlin, TM Vella, AW Flynn, JD Blakey et al. Experiences of Oral Corticosteroid Use and Adverse Effects: A National Cross-Sectional Survey of People with Asthma. Patient preference and adherence. 2025.

- AT Burge, NS Cox, S Dal Corso, AW Jones, FM Faqih, AE Holland. Cumulative Dispensing of Oral Corticosteroids Over 12 Months in People with COPD. International Journal of Chronic Obstructive Pulmonary Disease. 2025.
- G Tikellis, AE Holland. Health disparities and associated social determinants of health in interstitial lung disease: a narrative review. European Respiratory Review. 2025.
- M Graco, DJ Berlowitz, A Sawyer, AE Holland, KA Carey, Y Ahamed, et al. Polysomnographic titration of non-invasive ventilation in motor neurone disease (3TLA): protocol for a process evaluation of a clinical trial. 2025.
- LE Witjaksono, M Schulte, AE Holland, MS Wijsenbeek, YH Khor. Cough monitoring systems in adults with chronic respiratory diseases: a systematic review. European Respiratory Review. 2025.
- Z Ahmadi, NE Smallwood, AM Russell, R Saggu, L Romero, AE Holland, et al. Supplemental oxygen for symptomatic relief in people with serious respiratory illness: a systematic review and meta-analysis. European Respiratory Review. 2025.
- AT Burge, NS Cox, A Ponnudurai, AE Holland, J Bondarenko, CJ Hill, et al. Incidence of acute exacerbations of chronic respiratory disease during pulmonary rehabilitation delivered at home or hospital. 2025.
- AE Holland, C Bausewein, N Smallwood, M Ekström. Reply: A recommendation for increased airflow to relieve breathlessness: evidence in context is a strength of the GRADE approach. European Respiratory Journal. 2025
- NS Cox, AE Holland. Pulmonary rehabilitation: one size does not fit all. Thorax, 2025.
- AM Walker, DR Sullivan, P Nguyen, AE Holland, N Smallwood. Early, integrated palliative care for people with chronic respiratory disease: lessons learnt from lung cancer. Therapeutic Advances in Respiratory Disease. 2025.
- LM Glenn, D Jackson, C Barton, D Lan, L Fuhrmeister, K Symons, et al. Usability of a smartphone application for patients with interstitial lung disease: Results from the Registry for Better Understanding of ILD (RE-BUILD) pilot study. Respirology. 2025.
- YH Khor, V Poberezhets, RG Buhr, JD Chalmers, H Choi, VS Fan, et al. Assessment of Home-based Monitoring in Adults with Chronic Lung Disease: An Official American Thoracic Society Research Statement. American Journal of Respiratory and Critical Care Medicine. 2025.
- AK May, AE Holland, JA Alison, K Herrmann, NS Cox. Telerehabilitation services remain increased post-COVID-19 in Australia. Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation. 2025.
- NS Cox, S Dal Corso, AT Burge, J Bondarenko, J Perryman, AE Holland. Remote assessment of exercise capacity in adults with chronic respiratory disease: Safety, reliability and acceptability. Chronic Respiratory Disease. 2025.
- A Pascoe, AE Holland, N Smallwood. Challenges of symptom management in interstitial lung disease: dyspnea, cough and fatigue. Expert Review of Respiratory Medicine. 2025.

- LM Dowman, B Vainshelboim, AE Holland. Impact of pulmonary rehabilitation on survival in people with Interstitial lung disease. Chest. 2025.
- EM Webb, AE Holland, AB Chang, PG Middleton, R Thomson, C Wong, et al Pediatric physiotherapy management of airway clearance therapy and exercise: Data from the Australian Bronchiectasis Registry. Pediatric Pulmonology. 2025.
- AT Burge, NS Cox, AE Holland, CF McDonald, JA Alison, R Wootton, et al. Telerehabilitation Compared with Center-based Pulmonary Rehabilitation for People with Chronic Respiratory Disease: Economic Analysis of a Randomized Controlled Clinical Trial. Annals of the American Thoracic Society. 2025.
- C Jenkins, AP Dickens, A Evans, P Le Cheng, F Heraud, K Hancock, et al. Patterns of Care in the Management of High-Risk COPD in Australia (2015-2019): An Observational Study for the CONQUEST Quality Improvement Program. The Lancet Regional Health-Western Pacific. 2025.
- Y Hamada, PG Gibson, VL Clark, H Lewthwaite, M Fricker, D Thomas, McDonald VM. Dysfunctional breathing and depression are core extrapulmonary and behavior/risk factor traits in type 2-high severe asthma. The Journal of Allergy and Clinical. Immunology: In Practice. 2025.
- J Fingleton, R McLachlan, J Sparks, R Beasley, A Agustí, PG Gibson…VM McDonald. Treatable trait guided asthma management: A feasibility study. Respirology. 2025.
- SA Hiles, H Lewthwaite, VL Clark, AE Vertigan, A Smith, VM McDonald. Social determinants of mental health in asthma: an exploratory study. Frontiers in Allergy 5, 2025.
- NA Negewo, NM Niessen, PJ Baines, EJ Williams, N Fibbens…PG Gibson…VM McDonald et al.,. Targeted DNase treatment of obstructive lung disease: a pilot randomised controlled trial. ERJ Open Research. 2025.
- V Murphy, P Gibson, A Collison, W Karmaus, E Holliday, G Morgan, et al. Perinatal outcomes of bushfire smoke exposure in women with asthma. Journal of Allergy and Clinical Immunology. 2025.
- Y Hamada, PG Gibson, ES Harvey, S Stevens, H Lewthwaite, M Fricker, VM McDonald et al. Early Treatment Response to Mepolizumab Predicts Clinical Remission in Severe Eosinophilic Asthma. The Journal of Allergy and Clinical Immunology: In Practice. 2025.
- MR Sarwar, VM McDonald, MJ Abramson, S Wilson, AE Holland, et al. Credentialed pharmacist-led home medicines reviews targeting treatable traits and their impact on health outcomes in people with chronic obstructive pulmonary disease: a pre- and post-intervention study. International Journal of Clinical Pharmacy. 2025.
- Y Hamada, D Thomas, ES Harvey, S Stevens, M Fricker, H Lewthwaite, VM McDonald… PG Gibson et al. Distinct trajectories of treatment response to mepolizumab toward remission in patients with severe eosinophilic asthma. European Respiratory Journal. 2025.
- Peter Gerard Gibson. My Lungs Have Feelings Too! Respirology. 2025.
- Elena Kum; Gordon H. Guyatt; Rayid Abdulqawi; Peter Dicpinigaitis; Lieven Dupont; Stephen K. Field; Cynthia L. French; Peter G. Gibson; Richard S. Irwin;

Faye Johnston et al. The McMaster Cough Severity Questionnaire (MCSQ): a cough severity instrument for patients with refractory chronic cough. European Respiratory Journal. 2025.

- Bronwyn K Brew; Peter G Gibson; Adam M Collison; Joerg Mattes; Gabriela Martins; Costa Gomes; Annelies Robijn; Megan E Jensen; Wilfried Karmaus; Paul Robinson et al. 1Infant respiratory outcomes following asthma management and exacerbations in pregnancy. ERJ Open Research.
- Peter Gerard Gibson. The good doctor. Respirology. Contributors: 2025.
- Pavord ID, Gibson PG. 'Cough Reflex Hypersensitivity: A Common and Important Treatable Trait'. Journal of Allergy and Clinical Immunology: In Practice. 2025.
- Bronwyn K. Brew, Vanessa E. Murphy, Adam M. Collison, Joerg Mattes, Wilfried Karmaus, Geoffrey Morgan, Bin Jalaludin, Graeme Zosky, Yuming Guo, Peter G. Gibson. Approaches in landscape fire smoke pregnancy research and the impact on offspring: A review of knowledge gaps and recommendations, Environmental Pollution. 2025.
- Elvidge E, Murphy VE, Rao M, Gibson PG, McLaughlin K, Robijn A, et al., 'What are the broader impacts and value from a randomised controlled trial conducted in six public hospital antenatal clinics in Australia? An impact assessment using the Framework to Assess the Impact from Translational health research.' BMJ Open. 2025.
- 2025 Price OJ, Papadopoulos NG, Amérigo DA, Backer V, Bougault V, Del Giacco S, et al., 'Exercise Recommendations and Practical Considerations for Asthma Management An EAACI Position Paper', Allergy: European Journal of Allergy and Clinical Immunology. 2025.
- Leong P, Clark VL, Gibson PG, McDonald VM, Bardin PG, 'A Global Achievement: Introducing the Inducible Laryngeal Dysfunction/Vocal Cord Dysfunction Toolkit A Free Global, Peer-Reviewed Clinical Resource', Respirology, 2025.
- Jenkins C, Dickens AP, Evans A, Le Cheng P, Heraud F, Hancock K, et al., 'Patterns of care in the management of high-risk COPD in Australia (2015 2019): an observational study for the CONQUEST quality improvement program', The Lancet Regional Health – Western Pacific. 2025.
- Jensen ME, Harvey S, Dizon J, Holliday E, Weaver N, Barrass K, et al., 'Asthma, gestational diabetes and adverse perinatal outcomes: a population-based obstetrics records analysis.', The journal of allergy and clinical immunology. In practice. 2025.
- McLaughlin K, Jensen ME, Burke J, Drake J, Fredericks B, Johns A, et al., '"If I'm not getting oxygen, neither is my baby": A qualitative study of Australian women's experiences of asthma management in pregnancy', Women and Birth. 2025.
- Brew BK, Murphy VE, Collison AM, Mattes J, Karmaus W, Morgan G, et al., 'Approaches in landscape fire smoke pregnancy research and the impact on offspring: A review of knowledge gaps and recommendations', Environmental Pollution. 2025.

- Abraham E, Barlow RO, Bhatia R, Whalen OM, Beyene T, Murphy VE, 'Maternal exposure to particulate matter and nitrogen oxides during pregnancy and attention deficit hyperactivity disorder in offspring: a systematic review and meta-analysis', Reviews on Environmental Health. 2025.
- Elvidge E, Murphy VE, Rao M, Gibson PG, McLaughlin K, Robijn A, et al., 'What are the broader impacts and value from a randomised controlled trial conducted in six public hospital antenatal clinics in Australia? An impact assessment using the Framework to Assess the Impact from Translational health research.', BMJ Open. 2025.
- Jensen ME, Harvey S, Dizon J, Holliday E, Weaver N, Barrass K, et al., 'Asthma, gestational diabetes and adverse perinatal outcomes: a population-based obstetrics records analysis.', The journal of allergy and clinical immunology. In practice. 2025.
- LE Ruane, J Koh, M Baxter, P Finlay, K Low, R Hillman et al., Vocal cord dysfunction/inducible laryngeal obstruction induced by hyperventilation in healthy individuals, people with asthma, and following coronavirus infection. Journal of Asthma, 2025.
- Eathorne, A., et al. "Reducing ethnic inequities: Patterns of asthma medication use and hospital discharges in Māori in Aotearoa New Zealand." Respirology. 2025.
- Kung, S., et al. "Efficacy of Noninvasive Ventilation With Expiratory Washout in Stable COPD Patients." Respiratory Care. 2025.
- Meulmeester, F. L., et al. "Inflammatory and clinical risk factors for asthma attacks (ORACLE2): a patient-level meta-analysis of control groups of 22 randomised trials." The Lancet Respiratory Medicine. 2025.
- Couillard, S., et al. "Choosing the Right Biologic for the Right Patient With Severe Asthma." Chest. 2025.
- Dijk, L., Y. H. Gerritsma, T. Van der Molen, H. Kerstjens, J. Kocks, I. Pavord and R. J. Meijer et al., "Treatable Traits in Patients with Obstructive Lung Diseases in a Well-Established Asthma/COPD Service for Primary Care." International Journal of COPD. 2025.
- Fokkens, W. J., V. Backer, V. J. Lund, P. J. Barnes, M. Bernal-Sprekelsen, L. Bjermer, E. de Corso, D. M. Conti, M. E. Cornet, Z. Diamant, R. Djukanovic, M. Gaga, P. Gevaert, J. K. Han, C. Hopkins, G. Joos, B. N. Landis, S. Lau, S. E. Lee, J. Mullol, A. T. Peters, G. K. Scadding, S. Schneider, B. Senior, I. D. Pavord, S. Quirce, D. Ryan, M. E. Wechsler and P. W. Hellings. "Pocket guide: biologics in upper and lower airways in adults." Rhinology. 2025.
- Halpin, D. M. G., J. Balmes, M. K. Han, A. Papi, F. J. Martinez, M. M. de Oca, O. B. Ozoh, S. Salvi, D. D. Sin, J. Zheng, A. Agusti, C. Vogelmeier, A. Anzueto, J. Bourbeau, B. R. Celli, G. J. Criner, I. Pavord, N. Roche, D. Singh, R. Stockley, T. Troosters and J. A. Wedzicha. "Climate Change and Chronic Obstructive Pulmonary Disease A GOLD Science Committee Review." American Journal of Respiratory and Critical Care Medicine. 2025.
- Howell, I., A. Howell and I. Pavord. "Navigating uncertainty: asthma biologics during pregnancy." The Lancet Respiratory Medicine. 2025.

- Jesenak, M., A. Bobcakova, R. Djukanovic, M. Gaga, N. A. Hanania, L. G. Heaney, I. Pavord, S. Quirce, D. Ryan, W. Fokkens, D. Conti, P. W. Hellings, G. Scadding, E. Van Staeyen, L. H. Bjermer and Z. Diamant. "Promoting Prevention and Targeting Remission of Asthma: A EUFOREA Consensus Statement on Raising the Bar in Asthma Care." Chest. 2025.
- Lavoie, G., I. Howell, J. Melhorn, C. Borg, L. Bermejo-Sanchez, J. Seymour, M. F. Jabeen, A. Fries, G. Hynes, I. D. Pavord, N. Petousi and T. S. C. Hinks. "Effects of azithromycin in severe eosinophilic asthma with concomitant monoclonal antibody treatment." Thorax. 2025.
- Meulmeester, F. L., S. Mailhot-Larouche, C. Celis-Preciado, S. Lemaire-Paquette, S. Ramakrishnan, M. E. Wechsler, G. Brusselle, J. Corren, J. Hardy, S. E. Diver, C. E. Brightling, M. Castro, N. A. Hanania, D. J. Jackson, N. Martin, A. Laugerud, E. Santoro, C. Compton, M. E. Hardin, C. T. J. Holweg, A. Subhashini, T. S. C. Hinks, R. W. Beasley, J. K. Sont, E. W. Steyerberg, I. D. Pavord and S. Couillard. "Inflammatory and clinical risk factors for asthma attacks (ORACLE2): a patient-level meta-analysis of control groups of 22 randomised trials." The Lancet Respiratory Medicine. 2025.
- Pavord, I. D., C. E. Brightling, S. Korn, N. L. Martin, S. S. Ponnarambil, N. A. Molfino, J. R. Parnes and C. S. Ambrose. "Tezepelumab can Restore Normal Lung Function in Patients with Severe, Uncontrolled Asthma: Pooled Results from the PATHWAY and NAVIGATOR Studies." Pulmonary Therapy. 2025.
- Pavord, I. D., K. F. Rabe, E. Israel, S. J. Szefler, G. Brusselle, N. Pandit-Abid, A. Altincatal, Z. Chen, N. Amin, A. H. Khan, D. J. Lederer, Y. Zhang, P. J. Rowe, Y. Deniz, A. Radwan, J. A. Jacob-Nara and W. W. Busse. "Dupilumab Induces Long-Term On-Treatment Clinical Remission in Patients With Type 2 Asthma." Journal of Allergy and Clinical Immunology: In Practice. 2025.
- Pavord, I. D., M. E. Wechsler, W. W. Busse, C. Domingo, C. Xia, R. Gall, N. Pandit-Abid, J. A. Jacob-Nara, A. Radwan, P. J. Rowe and Y. Deniz. "Dupilumab efficacy in patients with type 2 asthma and early FENO level reductions." Journal of Allergy and Clinical Immunology: Global. 2025.
- Perikleous, A., S. J. Bowen, C. Griffiths, I. Pavord, M. Rosenthal, L. Fleming and A. Bush. "Blood Eosinophil Count: Lack of Stability and Association with Wheeze Attacks in Preschool Children." American Journal of Respiratory and Critical Care Medicine. 2025.
- Ramakrishnan, S., R. E. K. Russell, H. R. Mahmood, K. Krassowska, J. Melhorn, C. Mwasuku, I. D. Pavord, L. Bermejo-Sanchez, I. Howell, M. Mahdi, S. Peterson, T. Bengtsson and M. Bafadhel. "Treating eosinophilic exacerbations of asthma and COPD with benralizumab (ABRA): a double-blind, double-dummy, active placebo-controlled randomised trial." The Lancet Respiratory Medicine. 2025.
- Sciurba, F. C., G. J. Criner, S. A. Christenson, F. J. Martinez, A. Papi, N. Roche, J. Bourbeau, S. Korn, M. Bafadhel, M. K. Han, S. Kolterer, K. Miller, D. Mouneimne, J. Fletcher, B. Mayer, J. Min and I. D. Pavord. "Mepolizumab to Prevent Exacerbations of COPD with an Eosinophilic Phenotype." The New England journal of medicine. 2025.

- Singh, D., C. E. Brightling, K. F. Rabe, M. K. Han, S. A. Christenson, M. B. Drummond, A. Papi, I. D. Pavord, N. A. Molfino, G. Almqvist, A. Kotalik, Å. Hellqvist, M. Gołąbek, N. S. Sindhwani and S. S. Ponnarambil. "Efficacy and safety of tezepelumab versus placebo in adults with moderate to very severe chronic obstructive pulmonary disease (COURSE): a randomised, placebo-controlled, phase 2a trial." The Lancet Respiratory Medicine. 2025.
- Singh, D., R. Stockley, A. Anzueto, A. Agusti, J. Bourbeau, B. R. Celli, G. J. Criner, M. K. Han, F. J. Martinez, M. M. de Oca, O. B. Ozoh, A. Papi, I. Pavord, N. Roche, S. Salvi, D. D. Sin, T. Troosters, J. Wedzicha, J. Zheng, C. Volgelmeier and D. Halpin. "GOLD Science Committee recommendations for the use of pre- and post-bronchodilator spirometry for the diagnosis of COPD." European Respiratory Journal. 2025.
- Wechsler, M. E., I. D. Pavord, A. Papi, K. R. Chapman, A. Altincatal, N. Pandit-Abid, J. A. Jacob-Nara, P. J. Rowe, Y. Deniz, E. Laws, B. Akinlade, N. Amin, H. W. Staudinger, D. J. Lederer and M. Hardin. Long-Term Efficacy of Dupilumab in Moderate-to-Severe Asthma Phenotyped by Blood Eosinophils and Exhaled Nitric Oxide. CHEST Pulmonary. 2025.
- Hayes D, Jennerich AL, Coleman RD, Abston E, Adamson GT, Berger JT, et al., 'Interventional Strategies for Children with Progressive Pulmonary Hypertension Despite Optimal Therapy: An Official American Thoracic Society Clinical Practice Guideline.', Am J Respir Crit Care Med. 2025.
- Ekström M, Li PZ, Lewthwaite H, Bourbeau J, Tan WC, Jensen D, Canadian Cohort Obstructive Lung Disease Collaborative Research Group, 'Phenotyping Exertional Breathlessness Using Cardiopulmonary Cycle Exercise Testing in People With Chronic Airflow Limitation.', Chest. 2025.
- Ekström M, Lewthwaite H, Li PZ, Bourbeau J, Tan WC, Jensen D, CanCOLD Collaborative Research Group, 'Identifying Abnormal Exertional Breathlessness in COPD: Comparing Modified Medical Research Council and COPD Assessment Test With Cardiopulmonary Exercise Testing.', Chest. 2025.
- Hatter L, Beasley R. AIR Therapy: Improving Patient and Planetary Health Journal of Allergy and Clinical Immunology: In Practice. 2025.
- Bruce P, Houghton C, Hatter L, Kearns C, Holliday M, Anderson A.J, Perry M, Boyd C, Eathorne A, Martindale J, Sparks J, Semprini A, Pavord I, Harrison T, Papi A, Horne R, Weatherall M, Beasley R. An anti-inflammatory reliever algorithm approach to asthma management in adults: an open-label, single-arm trial. eClinicalMedicine. 2025.
- Mackle D.M, Nelson K, Beasley R.W, Eathorne A, Young P.J. The Influence of Participation in an Intensive Care Trial on Health Practitioners' Knowledge of the Results—A Self-Reported Survey. Journal of Advanced Nursing. 2025.
- Kung S, Semprini A.C, Kirton L.W, Fogarin J.R, Zoellner S.K, Beasley R, Eathorne A, Semprini R.A.C. Efficacy of Noninvasive Ventilation With Expiratory Washout in Stable COPD Patients Respiratory care. 2025.
- Noble J, Bean O, Sayers R, Cullen R, Kirton L, Eathorne A, Weatherall M, Beasley R. A framework to define an occasion of asthma reliever inhaler use. Journal of Allergy and Clinical Immunology: In Practice. 2025.

- Bird G, Sharpe S, Braithwaite I, Weatherall M, Beasley R. Nasopharyngeal Airspace Temperature During Rhinothermy. Respiratory care. 2025.
- Laforce C, Albers F, Danilewicz A, Jeynes-Ellis A, Kraft M, Panettieri R.A, Rees R, Bardsley S, Dunsire L, Harrison T, Sobande O, Surujbally R, Trudo F, Cappelletti C, Papi A, Beasley R, Chipps B.E, Israel E, Pandya H, Clancy M, Bacharier L.B. As-Needed Albuterol-Budesonide in Mild Asthma. New England Journal of Medicine. 2025.
- Noble J, Bean O, Sayers R, Cullen R, Beasley R, Weatherall M. External Validation of the Minimal Clinically Important Difference of FeNO Using the Asthma Control Questionnaire. Clinical and Experimental Allergy. 2025.
- Couillard S, Mailhot-Larouche S, Meulmeester F.L, Brusselle G, Lachapelle P, Beasley R.W, Sont J.K, Steyerberg E.W, Pavord I.D, Lugogo N. Normal FEV1 without Reversibility in Asthma Trials: A Placebo Patient-Level Meta-Analysis American journal of respiratory and critical care medicine. 2025.
- Yadav C.P, Chakraborty A, Price D.B, Lim L.H.M, Juang Y.R, Beasley R, Sadatsafavi M, Janson C, Siyue M.K, Wang E, Wechsler M.E, Jackson D.J, Busby J, Heaney L.G, Pfeffer P.E, Mahboub B, Perng D.-W, Cosio B.G, Perez-de-Llano L, Al-Lehebi R, Larenas-Linnemann D, Al-Ahmad M.S, Rhee C.K, Iwanaga T, Heffler E, Canonica G.W, Costello R.W, Papadopoulos N.G, Papaioannou A.I, Porsbjerg C.M, Torres-Duque C.A, Christoff G.C, Popov T.A, Hew M, Peters M.J, Gibson P.G, Máspero J, Bergeron C, Cerda S, Contreras E.A, Chen W. Prediction Pathway for Severe Asthma Exacerbations: A Bayesian Network Analysis. Chest. 2025.
- Howell I, Noble J, Howell A, Morgan C, Logan J, Miller S, Chaudhuri R, Russell R.E.K, Bafadhel M, Beasley R, Pavord I.D, Buckell J. The Risk–Benefit Balance of Oral Corticosteroid Treatment for Asthma Attacks: A Discrete Choice Experiment of Patients and Healthcare Professionals in the UK and New Zealand Respirology. 2025.
- Meulmeester F.L, Mailhot-Larouche S, Celis-Preciado C, Lemaire-Paquette S, Ramakrishnan S, Wechsler M.E, Brusselle G, Corren J, Hardy J, Diver S.E, Brightling C.E, Castro M, Hanania N.A, Jackson D.J, Martin N, Laugerud A, Santoro E, Compton C, Hardin M.E, Holweg C.T.J, Subhashini A, Hinks T.S.C, Beasley R.W, Sont J.K, Steyerberg E.W, Pavord I.D, Couillard S. Inflammatory and clinical risk factors for asthma attacks (ORACLE2): a patient-level meta-analysis of control groups of 22 randomised trials. The Lancet Respiratory Medicine. 2025.
- Hancox R.J, Beasley R, Beckert L, Chan A, Corna N, Fingleton J, Harwood M, Hurst M, Jones S, Jones S.L, Manderson Z, McNamara D, Poot B, Reid J, Trenholme A, Turner J. Review of the New Zealand Asthma and Respiratory Foundation's New Zealand Adolescent and Adult Asthma guidelines. New Zealand Medical Journal. 2025.
- Hatter L, Holliday M, Oldfield K, Kearns C, Barry T, Black M, Bruce P, Colman A, Dickinson E, Eathorne A, Harwood M, Hills T, Lamb R, Kerse K, Krishnamoorthy S, Martindale J, Semprini A, Shortt N, McNamara D, Byrnes C.A, Dalziel S.R, Bush A, Weatherall M, Beasley R. Budesonide–formoterol versus salbutamol as reliever therapy in children with mild asthma (CARE): a

52-week, open-label, multicentre, superiority, randomised controlled trial. The Lancet. 2025.
- Fingleton J, McLachlan R, Sparks J, Beasley R, Agustí A, Gibson P.G, Pavord I.D, Hardy J, Weatherall M, Eathorne A, McDonald V.M, Hardy J, Anderson A, Diputado L, Gilchrist J, Hardy J, Holliday M, Kerse K, Martindale J, Shortt N, Gibson P, Nikolajevic-Sarunac J, Smith A, Urroz P. Treatable Trait Guided Asthma Management: A Feasibility Study. Respirology. 2025.
- Noble J.H, Warhurst S, Cullen R, Sayers R, Lynch F, Kulathinal J, Weatherall M, Beasley R.W. The Dose-Response of Inhaled Corticosteroids in Combination Inhaled Corticosteroid/Long Acting Beta2-Agonist Maintenance Therapy for Asthma: A Systematic Review and Meta-Analysis. Chest. 2025.
- Derde L, Gordon A.C, Mouncey P.R, Al-Beidh F, Rowan K.M, Nichol A.D, Arabi Y.M, Annane D, Beane A, Beasley R, Bonten M.J.M, Bradbury C.A, Brunkhorst F.M, Buzgau A, Buxton M, Cheng A.C, Cooper N, Cove M, Cremer O.L, Detry M.A, Duffy E.J, Estcourt L.J, Fitzgerald M, Galea J, Goossens H, Haniffa R, Hills T.E, Huang D.T, Ichihara N, King A, Lamontagne F, Lawler P.R, Leavis H.L, Lewis R.J, Litton E, Marshall J.C, Mayr F.B, McAuley D.F, McGlothlin A, McGuinness S.P, McVerry B.J, Morpeth S.C, Murthy S, Netea M.G, Ogungbenro K, Orr K, Parke R.L, Parker J.C, Patanwala A.E, Pettila V, Reyes L.F, Saito H, Santos M.S, Saunders C.T, Seymour C.W, Shankar-Hari M, Sligl W.I, Turgeon A.F, Turner A.M, Tong S.Y.C, Vaara S, Youngstein T, Zarychanski R, Green C, Higgins A.M, McArthur C.J, Berry L.R, Lorenzi E, Berry S, Webb S.A, Angus D.C, van de Veerdonk F.L. Tocilizumab, sarilumab and anakinra in critically ill patients with COVID-19: a randomised, controlled, open-label, adaptive platform trial. Thorax. 2025.
- Eathorne A, Noble J, Hatter L, Hills T, Te Paa S, Harwood M, Weatherall M, Beasley R. Reducing ethnic inequities: Patterns of asthma medication use and hospital discharges in Māori in Aotearoa New Zealand. Respirology. 2025.
- Noble J, Bean O, Bruce P, Black M, Sayers R, Cullen R, Black B, Holliday M, Kirton L, Perry B, Eathorne A, Pavord I, Weatherall M, Beasley R. Protocol for the INFORM ASTHMA Trial: budesonide–formoterol reliever in adults with asthma on maintenance inhaled corticosteroid ERJ Open Research2025
- Kirton L.W, Eathorne A.L, Cook J.K, Hamill R.J, Kung S.M, Semprini A.C, Semprini R.A.C, Weatherall M, Beasley R. Automated Oxygen Titration With Noninvasive Respiratory Support in Acute In-Patient Care Respiratory care. 2025.
- Agusti A, Gibson PG, Heaney LG, Thomas M. Change is in the air: key questions on the 'Treatable Traits' model for chronic airway diseases in primary care. NPJ Prim Care Respir Med. 2024.
- Anderson WC, 3rd, Baptist AP, Eakin MN, Federman A, Murphy VE. Adherence Challenges and Strategies in Specific Groups With Asthma: Adolescents, Pregnancy, and Older Adults. J Allergy Clin Immunol Pract. 2024.
- Bacharier LB, Pavord ID, Maspero JF, Jackson DJ, Fiocchi AG, Mao X, et al. Blood eosinophils and fractional exhaled nitric oxide are prognostic and predictive biomarkers in childhood asthma. J Allergy Clin Immunol. 2024.
- Bardin P. VCD/ILO: Seeing and believing. Respirology. 2024.

- Bardin P. The raw stuff we cannot do without. Respirology. 2024.
- Bardin P. Cough suppression as a radical but effective therapeutic strategy. Respirology. 2024.
- Barry T, Holliday M, Sparks J, Biggs R, Colman A, Lamb R, et al. START CARE: a protocol for a randomised controlled trial of step-wise budesonide-formoterol reliever-based treatment in children. ERJ Open Res. 2024.
- Beasley R. Air pollution and global health: Need to prioritize alongside tobacco control. Respirology. 2024.
- Beasley R. The low hanging fruit of anti-inflammatory reliever therapy. Respirology. 2024.
- Beasley R, Ferreira DS, Papi A. As-needed Dual Inhaled Corticosteroid-Formoterol in Mild Asthma: Scientific Evidence. Arch Bronconeumol. 2024.
- Beasley R, Hughes R, Agusti A, Calverley P, Chipps B, Del Olmo R, et al. Prevalence, Diagnostic Utility and Associated Characteristics of Bronchodilator Responsiveness. Am J Respir Crit Care Med. 2024.
- Beasley R, Noble J. Time for the lens to focus on diagnostic algorithms in asthma. EClinicalMedicine. 2024.
- Beasley R, Noble J, Weatherall M. Extending Personalized Evidence-Based Medicine in Severe Asthma. J Allergy Clin Immunol Pract. 2024.
- Beasley R, Noble J, Weatherall M. The evidence base for ICS/formoterol maintenance and reliever therapy in severe asthma. Eur Respir J. 2024.
- Beyene T, Gibson PG, Murphy VE, Jensen ME, McDonald VM. Personal strategies to reduce the effects of landscape fire smoke on asthma-related outcomes: a protocol for systematic review and meta-analysis. BMJ Open. 2024.
- Bondarenko J, Dal Corso S, Dillon MP, Singh S, Miller BR, Kein C, et al. Clinically important changes and adverse events with centre-based or home-based pulmonary rehabilitation in chronic respiratory disease: A systematic review and meta-analysis. Chron Respir Dis. 2024.
- Boulet LP, Abbott C, Brusselle G, Edwards D, Oppenheimer J, Pavord ID, et al. Baseline Characteristics and ICS/LAMA/LABA Response in Asthma: Analyses From the CAPTAIN Study. J Allergy Clin Immunol Pract. 2024.
- Bourdin A, Brusselle G, Couillard S, Fajt ML, Heaney LG, Israel E, et al. Phenotyping of Severe Asthma in the Era of Broad-Acting Anti-Asthma Biologics. J Allergy Clin Immunol Pract. 2024.
- Brew BK, Murphy VE, Collison AM, Mattes J, Karmaus W, Morgan G, et al. Approaches in landscape fire smoke pregnancy research and the impact on offspring: A review of knowledge gaps and recommendations. Environ Pollut. 2025.
- Brightling CE, Caminati M, Llanos JP, Caveney S, Kotalik A, Griffiths JM, et al. Biomarkers and clinical outcomes after tezepelumab cessation: Extended follow-up from the 2-year DESTINATION study. Ann Allergy Asthma Immunol. 2024.
- Burge AT, Cox NS, Holland AE, McDonald CF, Alison JA, Wootton R, et al. Telerehabilitation Compared to Center-based Pulmonary Rehabilitation for

People with Chronic Respiratory Disease: Economic Analysis of a Randomized, Controlled Clinical Trial. Ann Am Thorac Soc. 2024.
- Burge AT, Gadowski AM, Jones A, Romero L, Smallwood NE, Ekström M, et al. Breathing techniques to reduce symptoms in people with serious respiratory illness: a systematic review. Eur Respir Rev. 2024.
- Burge AT, Gadowski AM, Romero L, Vagheggini G, Spathis A, Smallwood NE, et al. The effect of graded exercise therapy on fatigue in people with serious respiratory illness: a systematic review. Eur Respir Rev. 2024.
- Busse WW, Pavord ID, Wechsler ME, Davila IJ, Altincatal A, de Prado Gomez L, et al. Stability of Fractional Exhaled Nitric Oxide and its Relationship with Exacerbation in Patients Aged 6 Years or Older with Uncontrolled, Moderate-to-Severe Asthma. Chest. 2024.
- Caminati M, Buhl R, Corren J, Hanania NA, Kim H, Korn S, et al. Tezepelumab in patients with allergic and eosinophilic asthma. Allergy. 2024.
- Chan AHY, Leong P, Politis J, McDonald VM, Bardin P. Patient-reported outcomes: missing in asthma remission. Lancet Respir Med. 2024.
- Chen W, Tran TN, Sadatsafavi M, Murray RB, Boon Wong NC, Ali N, et al. Reply to "Exploring the long-term effects of biologic initiation in severe asthma: Insights from the International Severe Asthma Registry". J Allergy Clin Immunol Pract. 2024.
- Child CE, Ho LA, Lachant D, Gupta N, Moss J, Jones A, et al. Unsupervised Exercise in Interstitial Lung Disease: A Delphi Study to Develop a Consensus Preparticipation Screening Tool for Lymphangioleiomyomatosis. Chest. 2024.
- Chipps BE, Papi A, Beasley R, Israel E, Panettieri RA, Jr., Albers FC, et al. Albuterol-budesonide rescue reduces progression from asthma deterioration to severe exacerbation. J Allergy Clin Immunol Pract. 2024.
- Chong M, Holland AE, Burge AT, Perryman J, Cox NS. Telerehabilitation: a key player in reducing the travel emissions cost of respiratory healthcare? Eur Respir J. 2024.
- Couillard S, Jackson DJ, Pavord ID, Wechsler ME. Choosing the Right Biologic for the Right Patient With Severe Asthma. Chest. 2024.
- Cox ER, Plotnikoff RC, Gibson PG, Keating SE, Acharya S, Lewthwaite H. Prevalence of Long COVID and the Impact on Diabetes Management and Physical Activity Participation in Adults With Type 2 Diabetes: An Australia-wide Cross-sectional Online Survey. Can J Diabetes. 2024.
- Cox NS, Barton C, Bondarenko J, Clark R, Perryman J, Holland AE. Characterizing pulmonary rehabilitation referrals from primary care. Respir Med. 2024.
- Cox NS, Bondarenko J, Chong M, Marceu T, Perryman J, Holland AE. Rapid real-world implementation of pulmonary telerehabilitation: good fortune or COVID-19 luck? ERJ Open Res. 2024.
- Cox NS, Rawlings S, Lannin NA, Candy S, Bhatt SP, Babu AS, et al. Supporting delivery of remote pulmonary rehabilitation across different healthcare contexts: A multi-national study. Chron Respir Dis. 2024.

- Dal Corso S, Holland AE, George J, Abramson MJ, Russell G, Zwar N, et al. Fidelity of a home-based pulmonary rehabilitation program in people with COPD referred from primary care. Chron Respir Dis. 2024.
- De Queiroz Andrade E, Sena C, de Gouveia Belinelo P, Robinson PD, Blaxland A, Sly PD, et al. In utero smoking exposure induces changes to lung clearance index and modifies risk of wheeze in infants. Pediatr Pulmonol. 2024.
- Denton E, Hew M, Peters MJ, Upham JW, Bulathsinhala L, Tran TN, et al. Real-world biologics response and super-response in the International Severe Asthma Registry cohort. Allergy. 2024.
- Djukanović R, Brinkman P, Kolmert J, Gomez C, Schofield J, Brandsma J, et al. Biomarker Predictors of Clinical Efficacy of the Anti-IgE Biologic Omalizumab in Severe Asthma in Adults: Results of the SoMOSA Study. Am J Respir Crit Care Med. 2024.
- Doppen M, Kearns C, Hills T, Weatherall M, Beasley R. Intramuscular vaccination needle length: a call to arms. Lancet. 2024.
- Dowman LM, Holland AE. Pulmonary rehabilitation in idiopathic pulmonary fibrosis. Curr Opin Pulm Med. 2024.
- Duszyk K, McDonald VM, Thomas D, Steel K, Gibson PG. The treatable traits of asthma in pregnancy: a clinical audit. ERJ Open Res. 2024.
- Eapen AA, Gupta MR, Lockey RF, Bardin PG, Baptist AP. Gastroesophageal reflux disease, laryngopharyngeal reflux, and vocal cord dysfunction/inducible laryngeal obstruction-overlapping conditions that affect asthma. J Allergy Clin Immunol. 2024.
- Ferguson CE, Lambell KJ, Ridley EJ, Goh GS, Hodgson CL, Holland AE, et al. Muscularity of older trauma patients at intensive care unit admission, association with functional outcomes, and relationship with frailty: A retrospective observational study. Aust Crit Care. 2024.
- Freeman-Sanderson A, Crisp J, Hodgson CL, Holland AE, Harrold M, Chan T, et al. Prevalence, recovery, and factors associated with dysphagia in an older critically ill trauma cohort: A cross-sectional study. Aust Crit Care. 2024.
- Frei DR, Moore MR, Bailey M, Beasley R, Campbell D, Leslie K, et al. Associations between the intraoperative fraction of inspired intraoperative oxygen administration and days alive and out of hospital after surgery. BJA Open. 2024.
- Fricker M, Harrington J, Hiles SA, Gibson PG. Mepolizumab depletes inflammatory but preserves homeostatic eosinophils in severe asthma. Allergy. 2024.
- Garcia G, van Dijkman SC, Pavord I, Singh D, Oosterholt S, Fulmali S, et al. A Simulation Study of the Effect of Clinical Characteristics and Treatment Choice on Reliever Medication Use, Symptom Control and Exacerbation Risk in Moderate-Severe Asthma. Adv Ther. 2024.
- Gibson PG. The good doctor. Respirology. 2024.
- Gibson PG, McDonald VM. Integrating hot topics and implementation of treatable traits in asthma. Eur Respir J. 2024.

- Gibson PG, Urroz Guerrero PD, Poon C, Rutherford N, Brooker B, Smith A, et al. Ventilation Heterogeneity Is a Treatable Trait in Severe Asthma. J Allergy Clin Immunol Pract. 2024.
- Gomez HM, Haw TJ, Ilic D, Robinson P, Donovan C, Croft AJ, et al. Landscape fire smoke airway exposure impairs respiratory and cardiac function and worsens experimental asthma. J Allergy Clin Immunol. 2024.
- Hamada Y, Gibson PG, Harvey ES, Stevens S, Lewthwaite H, Fricker M, et al. Early Treatment Response to Mepolizumab Predicts Clinical Remission in Severe Eosinophilic Asthma. J Allergy Clin Immunol Pract. 2024.
- Hamada Y, Thomas D, Harvey ES, Stevens S, Fricker M, Lewthwaite H, et al. Distinct trajectories of treatment response to mepolizumab toward remission in patients with severe eosinophilic asthma. Eur Respir J. 2024.
- Hao Q, Brooks D, Ellerton C, Goldstein R, Lee AL, Alison JA, et al. Pulmonary rehabilitation with balance training for fall reduction in chronic obstructive pulmonary disease: a randomized controlled trial. BMC Pulm Med. 2024.
- Hatter L, Holliday M, Eathorne A, Bruce P, Pavord ID, Reddel HK, et al. The carbon footprint of as-needed budesonide/formoterol in mild asthma: a post hoc analysis. Eur Respir J. 2024.
- He LX, Deng K, Wang J, Zhang X, Wang L, Zhang HP, et al. Clinical Subtypes of Neutrophilic Asthma: A Cluster Analysis From Australasian Severe Asthma Network. J Allergy Clin Immunol Pract. 2024.
- Hoffman M, Burge AT, Wong N, McDonald CF, Chambers DC, Glaspole I, et al. Exertional Desaturation During the 6-Minute Walk Test vs Daily Life in People With Fibrotic Interstitial Lung Disease. Chest. 2024.
- Holland A, Corso SD. The Alfred Health post-COVID-19 service, Melbourne, 2020-2022: an observational cohort study. Med J Aust. 2024.
- Holland AE. Appraisal of Clinical Practice Guideline: Telerehabilitation in Physical Therapist Practice: A Clinical Practice Guideline From the American Physical Therapy Association. J Physiother. 2024.
- Holland AE, Dowman L. Using change in 6-minute walk distance to predict survival in progressive pulmonary fibrosis: A promising measure in need of precision. Respirology. 2024.
- Holland AE, Fineberg D, Marceau T, Chong M, Beaman J, Wilson L, et al. The Alfred Health post-COVID-19 service, Melbourne, 2020-2022: an observational cohort study. Med J Aust. 2024.
- Holland AE, Lewis A. Evidence-based management of symptoms in serious respiratory illness: what is in our toolbox? Eur Respir Rev. 2024.
- Holland AE, Spathis A, Marsaa K, Bausewein C, Ahmadi Z, Burge AT, et al. European Respiratory Society clinical practice guideline on symptom management for adults with serious respiratory illness. Eur Respir J. 2024.
- Holland AE, Woollett A, Goh N, Glaspole I. Respiratory teletrials-A call for equitable access to clinical trials for people with respiratory conditions. Respirology. 2024.
- Howell I, Bratton DJ, Hynes G, Yancey SW, Heaney LG, Pavord ID, et al. Clinical characterisation of exacerbations of severe eosinophilic asthma occurring on mepolizumab and placebo. ERJ Open Res. 2024.

- Howell I, Howell A, Pavord I. Navigating uncertainty: asthma biologics during pregnancy. Lancet Respir Med. 2024.
- Howell I, Howell A, Ramakrishnan S, Bafadhel M, Pavord I. How have we measured trial outcomes of asthma attack treatment? A systematic review. ERJ Open Res. 2024.
- Howell I, Yang F, Brown V, Cane J, Marchi E, Azim A, et al. Airway proteomics reveals broad residual anti-inflammatory effects of prednisolone in mepolizumab-treated asthma. J Allergy Clin Immunol. 2024.
- Huang D, Zhang L, Liu Y, Wang J, Zhang J, Baines KJ, et al. Activated non-neuronal cholinergic system correlates with non-type 2 inflammation and exacerbations in severe asthma. Ann Allergy Asthma Immunol. 2024.
- Jabeen MF, Sanderson ND, Tinè M, Donachie G, Barber C, Azim A, et al. Species-level, metagenomic and proteomic analysis of microbe-immune interactions in severe asthma. Allergy. 2024;79(11):2966-80.
- Jackson DJ, Wechsler ME, Jackson DJ, Bernstein D, Korn S, Pfeffer PE, et al. Twice-Yearly Depemokimab in Severe Asthma with an Eosinophilic Phenotype. N Engl J Med. 2024.
- Jeffery J, Vertigan AE, Bone S, Gibson PG. Abnormal breathing pattern features in chronic refractory cough. ERJ Open Res. 2024.
- Jenkins AR, Burtin C, Camp PG, Lindenauer P, Carlin B, Alison JA, et al. Do pulmonary rehabilitation programmes improve outcomes in patients with COPD posthospital discharge for exacerbation: a systematic review and meta-analysis. Thorax. 2024.
- Jenkins AR, Cox NS, Tappan RS, Holland AE, Rochester CL, Alison JA, et al. Summary for Clinicians: Clinical Practice Guideline on Pulmonary Rehabilitation for Adults with Chronic Respiratory Disease. Ann Am Thorac Soc. 2024.
- Jones AW, King BE, Cumella A, Hopkinson NS, Hurst JR, Holland AE. Use of infection control measures in people with chronic lung disease: mixed methods study. ERJ Open Res. 2024;10(1).
- Keijzers G, Donaghy M, Weatherall M, Beasley R, Ball EL, Simpson G, et al. Primary spontaneous pneumothorax: does size matter? Eur Respir J. 2024.
- Khaleva E, Brightling C, Eiwegger T, Altraja A, Bégin P, Blumchen K, et al. Patient-centred composite scores as tools for assesment of response to biological therapy for paediatric and adult severe asthma. Eur Respir J. 2024.
- Khor YH, Poberezhets V, Buhr RG, Chalmers JD, Choi H, Fan VS, et al. Assessment of Home-based Monitoring in Adults with Chronic Lung Disease. An Official American Thoracic Society Research Statement. Am J Respir Crit Care Med. 2024.
- Kimmel LA, Raper E, Harris IA, Ackerman IN, Page R, Naylor JM, et al. HIP fracture Supplemental Therapy to Enhance Recovery (HIPSTER): a protocol for a randomised controlled trial. BMJ Open. 2024.
- Kirton L, Kung S, Bird G, Black M, Semprini R, Eathorne A, et al. Automated oxygen titration with non-invasive ventilation in hypoxaemic adults with cardiorespiratory disease: a randomised cross-over trial. BMJ Open Respir Res. 2024.

- Kirton LW, Cruz RS, Navarra L, Eathorne A, Cook J, Beasley R, et al. Effect of automated titration of oxygen on time spent in a prescribed oxygen saturation range in adults in the ICU after cardiac surgery. Crit Care Resusc. 2024.
- Kok HC, McCallum GB, Yerkovich ST, Grimwood K, Fong SM, Nathan AM, et al. Twenty-four Month Outcomes of Extended- Versus Standard-course Antibiotic Therapy in Children Hospitalized With Pneumonia in High-risk Settings: A Randomized Controlled Trial. Pediatr Infect Dis J. 2024.
- Krings JG, Beasley R. The Role of ICS-Containing Rescue Therapy Versus SABA Alone in Asthma Management Today. J Allergy Clin Immunol Pract. 2024.
- Kuek SL, Wong NX, Dalziel S, Hatter L, Fleming L, Bush A, et al. Dry-powder inhaler use in primary school-aged children with asthma: a systematic review. ERJ Open Res. 2024.
- Kum E, Guyatt GH, Abdulqawi R, Dicpinigaitis P, Dupont L, Field SK, et al. The McMaster Cough Severity Questionnaire (MCSQ): a cough severity instrument for patients with refractory chronic cough. Eur Respir J. 2024.
- Kung S, Semprini AC, Kirton LW, Fogarin JR, Zoellner SK, Beasley R, et al. Efficacy of Noninvasive Ventilation With Expiratory Washout in Stable COPD Patients. Respir Care. 2024.
- Lamb R, Kerse K, Kristono H, Oldfield K, Beasley R. A snapshot of SABA co-prescribing with ICS-formoterol maintenance and reliever therapy. Respirology. 2024.
- Lavoie G, Pavord ID. Biologics in Asthma: Role of Biomarkers. Immunol Allergy Clin North Am. 2024.
- Lee JYT, Tikellis G, Hoffman M, Mellerick CR, Symons K, Bondarenko J, et al. A self-management package for pulmonary fibrosis: A feasibility study. PEC Innov. 2024.
- Lee TY, Price D, Yadav CP, Roy R, Lim LHM, Wang E, et al. International Variation in Severe Exacerbation Rates in Patients With Severe Asthma. Chest. 2024.
- Levy ML, Beasley R, Bostock B, Capstick TG, Crooks MG, Fleming L, et al. A simple and effective evidence-based approach to asthma management: ICS-formoterol reliever therapy. Br J Gen Pract. 2024.
- Lewthwaite H, Gibson PG, Guerrero PDU, Smith A, Clark VL, Vertigan AE, et al. Understanding Breathlessness Burden and Psychophysiological Correlates in Asthma. J Allergy Clin Immunol Pract. 2024.
- Loewenthal L, Busby J, McDowell R, Brown T, Burhan H, Chaudhuri R, et al. Impact of sex on severe asthma: a cross-sectional retrospective analysis of UK primary and specialist care. Thorax. 2024.
- Lommatzsch M, Buhl R, Canonica GW, Ribas CD, Nagase H, Brusselle GG, et al. Pioneering a paradigm shift in asthma management: remission as a treatment goal. Lancet Respir Med. 2024.
- Luo J, Chen W, Liu W, Jiang S, Ye Y, Shrimanker R, et al. IL-5 antagonism reverses priming and activation of eosinophils in severe eosinophilic asthma. Mucosal Immunol. 2024.

- Mackintosh JA, Keir G, Troy LK, Holland AE, Grainge C, Chambers DC, et al. Treatment of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis: A position statement from the Thoracic Society of Australia and New Zealand 2023 revision. Respirology. 2024.
- Mackle DM, Nelson K, Beasley RW, Eathorne A, Young PJ. The Influence of Participation in an Intensive Care Trial on Health Practitioners' Knowledge of the Results-A Self-Reported Survey. J Adv Nurs. 2024.
- Majellano EC, Clark VL, Vertigan A, Gibson PG, Bardin P, Leong P, et al. Living With Asthma and Vocal Cord Dysfunction/Inducible Laryngeal Obstruction: "I Just Can't Get Air In". J Allergy Clin Immunol Pract. 2024.
- Majellano EC, Yorke J, Clark VL, Gibson PG, Smith AJ, Holmes LJ, et al. The illness burden of severe asthma contrasted to people with mild-to-moderate asthma: a qualitative study. ERJ Open Res. 2024.
- Maneechotesuwan K, Aggarwal B, Garcia G, Tan D, Neffen H, Javier RJM, et al. Exploring Clinical Remission in Moderate Asthma – Perspectives from Asia, the Middle East, and South America. Pulm Ther. 2024.
- Marchant JM, Chang AB, Kennedy E, King D, Perret JL, Schultz A, et al. Cough in Children and Adults: Diagnosis, Assessment and Management (CICADA). Summary of an updated position statement on chronic cough in Australia. Med J Aust. 2024.
- Martins Costa Gomes G, Da Silva Sena CR, Murphy VE, Hansbro PM, Starkey MR, Gibson PG, et al. Cord blood granulocyte levels are associated with severe bronchiolitis in the first year of life. Clin Transl Immunology. 2024.
- May AK, Holland AE, Alison JA, Herrmann K, Cox NS. Telerehabilitation Services Remain Increased Post-COVID-19 in Australia. Chronic Obstr Pulm Dis. 2024.
- McDonald CF, Bardin PG, MacDonald M. Asthma-COPD overlap and asthma progressing to COPD: A complementary perspective. Respirology. 2024.
- McDonald VM. Let's talk about obesity in respiratory disease. Respirology. 2024.
- McDonald VM, Gibson PG. Treatable traits-Where we are, where we are headed. Respirology. 2024.
- McDonald VM, Hamada Y, Agusti A, Gibson PG. Treatable Traits in Asthma: The Importance of Extrapulmonary Traits-GERD, CRSwNP, Atopic Dermatitis, and Depression/Anxiety. J Allergy Clin Immunol Pract. 2024.
- McDonald VM, Holland AE. Treatable traits models of care. Respirology. 2024.
- Mellerick CR, Burge AT, Hill CJ, Cox NS, Bondarenko J, Holland AE. Impact of Test Instructions on 6-min Walk Distance in Adults With Chronic Respiratory Disease: A Randomized Controlled Trial. J Cardiopulm Rehabil Prev. 2024.
- Murphy VE, Whalen OM, Williams EJ, Gibson PG, Campbell LE, Karayanidis F, et al. Autism likelihood in infants born to mothers with asthma is associated with blood inflammatory gene biomarkers in pregnancy. Brain Behav Immun Health. 2024.
- Newman ANL, Beauchamp MK, Ellerton C, Goldstein R, Alison JA, Dechman G, et al. Reflections on the challenges of conducting an international multicentre randomized controlled trial of balance training in addition to pulmonary

rehabilitation and its impact on fall incidence in people with COPD. Trials. 2024.
- Nguyen KT, Brooks D, Macedo LG, Ellerton C, Goldstein R, Alison JA, et al. Balance measures for fall risk screening in community-dwelling older adults with COPD: A longitudinal analysis. Respir Med. 2024.
- Noble J, Hatter L, Eathorne A, Hills T, Bean O, Bruce P, et al. Patterns of asthma medication use and hospital discharges in New Zealand. J Allergy Clin Immunol Glob. 2024.
- O'Driscoll BR, Kirton L, Weatherall M, Bakerly ND, Turkington P, Cook J, et al. Effect of a lower target oxygen saturation range on the risk of hypoxaemia and elevated NEWS2 scores at a university hospital: a retrospective study. BMJ Open Respir Res. 2024.
- Oliveira JM, Clark VL, Furlanetto KC, Gibson PG, McDonald VM. Core Function in Adults With Severe Asthma and Its Relationship With Breathing Symptoms. J Allergy Clin Immunol Pract. 2024.
- Oliveira MR, Hoffman M, Jones AW, Holland AE, Borghi-Silva A. Effect of Pulmonary Rehabilitation on Exercise Capacity, Dyspnea, Fatigue, and Peripheral Muscle Strength in Patients With Post-COVID-19 Syndrome: A Systematic Review and Meta-analysis. Arch Phys Med Rehabil. 2024.
- Oppenheimer J, Kerstjens HA, Boulet LP, Hanania NA, Kerwin E, Moore A, et al. Characterization of Moderate and Severe Asthma Exacerbations in the CAPTAIN Study. J Allergy Clin Immunol Pract. 2024.
- Papi A, Castro M, Corren J, Pavord ID, Tohda Y, Altincatal A, et al. Dupilumab sustains lung function improvements in patients with moderate-to-severe asthma. Respir Med. 2024.
- Papi A, Chipps BE, Beasley R, Panettieri RA, Jr., Israel E, Cooper M, et al. Albuterol-budesonide fixed-dose combination rescue inhaler for asthma: a plain language summary of the MANDALA study. Ther Adv Respir Dis. 2024.
- Papi A, Faner R, Pavord I, Baraldi F, McDonald VM, Thomas M, et al. From treatable traits to GETomics in airway disease: moving towards clinical practice. Eur Respir Rev. 2024.
- Pavord I, Chan R, Brown N, Howarth P, Gilson M, Price RG, et al. Long-term safety of mepolizumab for up to ~10 years in patients with severe asthma: open-label extension study. Ann Med. 2024.
- Pavord ID. Remission in the World of Severe Asthma. Am J Respir Crit Care Med. 2024.
- Pavord ID. The Rebirth of Lebrikizumab for Airway Disease. J Allergy Clin Immunol Pract. 2024.
- Pavord ID. New thinking and a new direction in bronchiectasis. Lancet Respir Med. 2024.
- Pavord ID, Casale TB, Corren J, FitzGerald MJ, Deniz Y, Altincatal A, et al. Dupilumab Reduces Exacerbations Independent of Changes in Biomarkers in Moderate-to-Severe Asthma. J Allergy Clin Immunol Pract. 2024.
- Pavord ID, De Prado Gómez L, Brusselle G, Jackson DJ, Brightling CE, Papi A, et al. Biomarkers Associated with Lung Function Decline and Dupilumab Response in Patients with Asthma. Am J Respir Crit Care Med. 2024.

- Pavord ID, Rabe KF, Israel E, Szefler SJ, Brusselle G, Pandit-Abid N, et al. Dupilumab Induces Long-term On-Treatment Clinical Remission in Patients With Type 2 Asthma. J Allergy Clin Immunol Pract. 2024.
- Pelaia C, Melhorn J, Hinks TS, Couillard S, Vatrella A, Pelaia G, et al. Type 2 severe asthma: pathophysiology and treatment with biologics. Expert Rev Respir Med. 2024.
- Perez-de-Llano L, Scelo G, Canonica GW, Chen W, Henley W, Larenas-Linnemann D, et al. Impact of pre-biologic impairment on meeting domain-specific biologic responder definitions in patients with severe asthma. Ann Allergy Asthma Immunol. 2024.
- Perez-de-Llano L, Scelo G, Tran TN, Le TT, Fageråas M, Cosio BG, et al. Exploring Definitions and Predictors of Severe Asthma Clinical Remission after Biologic Treatment in Adults. Am J Respir Crit Care Med. 2024.
- Perikleous A, Bowen SJ, Griffiths C, Pavord I, Rosenthal M, Fleming L, et al. Blood Eosinophil Count: Lack of Stability and Association with Wheeze Attacks in Preschool Children. Am J Respir Crit Care Med. 2024.
- Petousi N, Pavord ID, Kent BD. Type-2 inflammation: a key treatable trait associated with lung function decline in chronic airways disease. Thorax. 2024.
- Pizzichini E, Brusselle G, Edwards D, Gibson PG, Kerstjens HA, Moore A, et al. Run-in periods and treatment outcomes in asthma trials: A narrative review. Contemp Clin Trials Commun. 2024.
- Politis J, Bardin PG, Leong P. Contemporary Concise Review 2023: Asthma. Respirology. 2024.
- Politis J, Chung LP, Igwe E, Bardin P, Gibson PG. Oral corticosteroid stewardship: key insights from the Australasian Severe Asthma Registry. Intern Med J. 2024.
- Porsbjerg CM, Townend J, Bergeron C, Christoff GC, Katsoulotos GP, Larenas-Linnemann D, et al. Association between pre-biologic T2-biomarker combinations and response to biologics in patients with severe asthma. Front Immunol. 2024.
- Poulsen M, Holland AE, Button B, Jones AW. Preferences and perspectives regarding telehealth exercise interventions for adults with cystic fibrosis: A qualitative study. Pediatr Pulmonol. 2024.
- Ramakrishnan S, Montgomery B, Pavord ID. Blood eosinophils and lung function loss: from passive prediction to active prevention? Eur Respir J. 2024.
- Ramakrishnan S, Russell REK, Mahmood HR, Krassowska K, Melhorn J, Mwasuku C, et al. Treating eosinophilic exacerbations of asthma and COPD with benralizumab (ABRA): a double-blind, double-dummy, active placebo-controlled randomised trial. Lancet Respir Med. 2024.
- Raper E, Kimmel LA, Burge AT, Harris IA, Ackerman IN, Page RS, et al. Implementation of supplemental physiotherapy following hip fracture surgery: a protocol for the process evaluation of a randomised controlled trial. Trials. 2024.
- Raymond MJ, Christie LJ, Kramer S, Malaguti C, Mok Z, Gardner B, et al. Delivery of Allied Health Interventions Using Telehealth Modalities: A Rapid

Systematic Review of Randomized Controlled Trials. Healthcare (Basel). 2024.
- Robijn AL, Harvey SM, Jensen ME, Atkins S, Quek KJD, Wang G, et al. Adverse neonatal outcomes in pregnant women with asthma: An updated systematic review and meta-analysis. Int J Gynaecol Obstet. 2024.
- Ruane LE, Denton E, Bardin PG, Leong P. Dysfunctional breathing or breathing pattern disorder: New perspectives on a common but clandestine cause of breathlessness. Respirology. 2024.
- Rupani H, Busse WW, Howarth PH, Bardin PG, Adcock IM, Konno S, et al. Therapeutic relevance of eosinophilic inflammation and airway viral interactions in severe asthma. Allergy. 2024.
- Russell RJ, Boulet LP, Brightling CE, Pavord ID, Porsbjerg C, Dorscheid D, et al. The airway epithelium: an orchestrator of inflammation, a key structural barrier and a therapeutic target in severe asthma. Eur Respir J. 2024.
- Sarwar MR, McDonald VM, Abramson MJ, Wilson S, Holland AE, Bonevski B, et al. Credentialed pharmacist-led home medicines reviews targeting treatable traits and their impact on health outcomes in people with chronic obstructive pulmonary disease: a pre- and post-intervention study. Int J Clin Pharm. 2024.
- Scelo G, Torres-Duque CA, Maspero J, Tran TN, Murray R, Martin N, et al. Analysis of comorbidities and multimorbidity in adult patients in the International Severe Asthma Registry. Ann Allergy Asthma Immunol. 2024.
- Scelo G, Tran TN, Le TT, Fagerås M, Dorscheid D, Busby J, et al. Exploring Definitions and Predictors of Response to Biologics for Severe Asthma. J Allergy Clin Immunol Pract. 2024.
- Sena C, Morten M, Collison AM, Shaar A, Andrade EQ, Meredith J, et al. Bronchiolitis hospital admission in infancy is associated with later preschool ventilation inhomogeneity. Pediatr Pulmonol. 2024.
- Singh D, Brightling CE, Rabe KF, Han MK, Christenson SA, Drummond MB, et al. Efficacy and safety of tezepelumab versus placebo in adults with moderate to very severe chronic obstructive pulmonary disease (COURSE): a randomised, placebo-controlled, phase 2a trial. Lancet Respir Med. 2024.
- Singh D, Stockley R, Anzueto A, Agusti A, Bourbeau J, Celli BR, et al. GOLD Science Committee recommendations for the use of pre- and post-bronchodilator spirometry for the diagnosis of COPD. Eur Respir J. 2024.
- Smallwood NE, Pascoe A, Wijsenbeek M, Russell AM, Holland AE, Romero L, et al. Opioids for the palliation of symptoms in people with serious respiratory illness: a systematic review and meta-analysis. Eur Respir Rev. 2024.
- Smolinska S, Popescu FD, Izquierdo E, Antolín-Amérigo D, Price OJ, Alvarez-Perea A, et al. Telemedicine with special focus on allergic diseases and asthma-Status 2022: An EAACI position paper. Allergy. 2024.
- Spathis A, Reilly CC, Bausewein C, Reinke LF, Romero L, Smallwood NE, et al. Multicomponent services for symptoms in serious respiratory illness: a systematic review and meta-analysis. Eur Respir Rev. 2024.
- Thomas D, McDonald VM, Gibson PG. Realignment of clinical research after the COVID-19 era. Lancet Respir Med. 2024.

- Thomas D, McDonald VM, Stevens S, Baraket M, Hodge S, James A, et al. Effect of Azithromycin on Asthma Remission in Adults With Persistent Uncontrolled Asthma: A Secondary Analysis of a Randomized, Double-Anonymized, Placebo-Controlled Trial. Chest. 2024.
- Thomas D, McDonald VM, Stevens S, Harvey ES, Baraket M, Bardin P, et al. Biologics (mepolizumab and omalizumab) induced remission in severe asthma patients. Allergy. 2024.
- Thottiyil Sultanmuhammed Abdul Khadar B, Sim J, McDonald VM, McDonagh J, Clapham M, Mitchell BG. Air Purifiers and Acute Respiratory Infections in Residential Aged Care: A Randomized Clinical Trial. JAMA Netw Open. 2024.
- Tikellis G, Corte T, Glaspole IN, Goh NSL, Khor YH, Wrobel J, et al. Navigating the COVID-19 pandemic: Experiences and self-management approaches adopted by people with interstitial lung disease. Chron Respir Dis. 2024.
- Urroz Guerrero PD, Gibson PG, Lewthwaite H, Majellano E, Hiles SA, McDonald VM. Perceptions of sedentary behaviour in people with severe asthma: a qualitative study. BMC Public Health. 2024.
- Urroz Guerrero PD, Lewthwaite H, Gibson PG, Clark VL, Cordova-Rivera L, McDonald VM. Physical capacity and inactivity in obstructive airway diseases: a “can do, do do” analysis. ERJ Open Res. 2024.
- Valkenborghs SR, Wood LG, Callister R, Upham JW, Grainge CL, Anderson S, et al. Effects of Moderate- Versus Vigorous-Intensity Exercise Training on Asthma Outcomes in Adults. J Allergy Clin Immunol Pract. 2024.
- van Dijkman SC, Yorgancıoğlu A, Pavord I, Brusselle G, Pitrez PM, Oosterholt S, et al. Effect of Individual Patient Characteristics and Treatment Choices on Reliever Medication Use in Moderate-Severe Asthma: A Poisson Analysis of Randomised Clinical Trials. Adv Ther. 2024.
- Webb EM, Holland AE, Chang AB, Burr L, Holmes-Liew CL, King PT, et al. Current physiotherapy practice for adults with bronchiectasis: Data from the Australian bronchiectasis registry. Respir Med. 2024.
- Webb EM, Holland AE, Chang AB, Middleton PG, Thomson R, Wong C, et al. Pediatric physiotherapy management of airway clearance therapy and exercise: Data from the Australian Bronchiectasis Registry. Pediatr Pulmonol. 2024.
- Wechsler ME, Brusselle G, Virchow JC, Bourdin A, Kostikas K, Llanos JP, et al. Clinical response and on-treatment clinical remission with tezepelumab in a broad population of patients with severe, uncontrolled asthma: results over 2 years from the NAVIGATOR and DESTINATION studies. Eur Respir J. 2024.
- Wechsler ME, Scelo G, Larenas-Linnemann DES, Torres-Duque CA, Maspero J, Tran TN, et al. Association Between T2-related Comorbidities and Effectiveness of Biologics in Severe Asthma. Am J Respir Crit Care Med. 2024.
- Whalen OM, Campbell LE, Lane AE, Karayanidis F, Mallise CA, Woolard AJ, et al. Effect of fractional exhaled nitric oxide (F(ENO))-based asthma management during pregnancy versus usual care on infant development, temperament, sensory function and autism signs. Eur J Pediatr. 2024.
- Thomas D, McDonald VM, Stevens S, Baraket M, Hodge S, James A, et al., 'Azithromycin induced asthma remission in adults with persistent uncontrolled

asthma: a secondary analysis of a randomised, double-blind, placebo-controlled trial.', Chest, 10.1016/j.chest.2024.02.048. 2024.
- McDonald VM, 'Let's talk about obesity in respiratory disease.', Respirology. 2024.
- Majellano EC, Clark VL, Vertigan A, Gibson PG, Bardin P, Leong P, McDonald VM, 'Living With Asthma and Vocal Cord Dysfunction/Inducible Laryngeal Obstruction: "I Just Can't Get Air In".', J Allergy Clin Immunol Pract. 2024.
- Oliveira JM, Clark VL, Furlanetto KC, Gibson PG, McDonald VM, 'Core Function In Adults With Severe Asthma and Its Relationship With Breathing Symptoms.', J Allergy Clin Immunol Pract. 2024.
- Mcdonald VM, Holland AE, 'Treatable traits models of care', Respirology. 2024.
- McDonald VM, Hamada Y, Agusti A, Gibson PG, 'Treatable Traits in Asthma: The Importance of Extrapulmonary Traits GERD, CRSwNP, Atopic Dermatitis, and Depression/Anxiety', The Journal of Allergy and Clinical Immunology: In Practice. 2024.
- Sena CRDS, Morten M, Collison AM, Shaar A, Andrade EDQ, Meredith J, et al., 'Bronchiolitis hospital admission in infancy is associated with later preschool ventilation inhomogeneity.', Pediatr Pulmonol. 2024.
- McDonald VM, Hamada Y, Agusti A, Gibson PG, 'Treatable Traits in Asthma: The Importance of Extrapulmonary Traits GERD, CRSwNP, Atopic Dermatitis, and Depression/Anxiety', The Journal of Allergy and Clinical Immunology: In Practice. 2024.
- Wechsler ME, Scelo G, Larenas-Linnemann DES, Torres-Duque CA, Maspero J, Tran TN, et al., 'Association Between T2-related Comorbidities and Effectiveness of Biologics in Severe Asthma.', Am J Respir Crit Care Med. 2024.
- Beyene T, Gibson PG, Murphy VE, Jensen ME, McDonald VM, 'Personal strategies to reduce the effects of landscape fire smoke on asthma-related outcomes: a protocol for systematic review and meta-analysis.', BMJ Open. 2024.
- Robijn AL, Harvey SM, Jensen ME, Atkins S, Quek KJD, Wang G, et al., 'Adverse neonatal outcomes in pregnant women with asthma: An updated systematic review and meta-analysis.', Int J Gynaecol Obstet. 2024.
- Boulet L-P, Abbott C, Brusselle G, Edwards D, Oppenheimer J, Pavord ID, et al., 'Baseline characteristics and ICS/LAMA/LABA response in asthma: analyses from the CAPTAIN study.', J Allergy Clin Immunol Pract. 2024.
- Duszyk K, Marie McDonald V, Thomas D, Steel K, Gerard Gibson P, 'The treatable traits of asthma in pregnancy: a clinical audit', ERJ Open Research. 2024.
- Gibson PG, 'Local knowledge: Every surfer knows the feeling', Respirology. 2024.
- Thomas D, McDonald VM, Stevens S, Harvey ES, Baraket M, Bardin P, et al., 'Biologics (mepolizumab and omalizumab) induced remission in severe asthma patients.', Allergy. 2024.

- Scelo G, Torres-Duque CA, Maspero J, Tran TN, Murray R, Martin N, et al., 'Analysis of comorbidities and multimorbidity in adult patients in the International Severe Asthma Registry.', Ann Allergy Asthma Immunol. 2024.
- Chen W, Tran TN, Sadatsafavi M, Murray RB, Boon Wong NC, Ali N, et al., 'Reply to "Exploring the long-term effects of biologic initiation in severe asthma: Insights from the International Severe Asthma Registry". J Allergy Clin Immunol Pract. 2024.
- Frei, Daniel R, Moore, Matthew R, Bailey, Michael; Beasley, Richard; Campbell, Douglas; Leslie, Kate; Myles, Paul S, Short, Timothy G, Young, Paul J. Associations between the intraoperative fraction of inspired intraoperative oxygen administration and days alive and out of hospital after surgery. BJA-Open. 2024.
- Beasley, Richard The low hanging fruit of anti-inflammatory reliever therapy. Respirology. 2024.
- Levy, Mark L; Beasley, Richard; Bostock, Bev; Capstick, Toby GD; Crooks, Michael G; Fleming, Louise; Freeman, Daryl; Marsh, Viv; Rupani, Hitasha; Whittamore, Andy et al. A simple and effective evidence-based approach to asthma management: ICS-formoterol reliever therapy. British Journal of General Practice. 2024.
- Beasley, Richard; Hughes, Rod; Agusti, Alvar; Calverley, Peter; Chipps, Bradley; Olmo, Ricardo del; Papi, Alberto; Price, David; Reddel, Helen; Müllerová, Hana et al. Prevalence, Diagnostic Utility and Associated Characteristics of Bronchodilator Responsiveness. American Journal of Respiratory and Critical Care Medicine. 2024.
- Jenkins, Christine R, Phillip Bardin. The long and winding road—Where to now for asthma? Respirology. 2024.
- Bardin, Philip. The raw stuff we cannot do without. Respirology. 2024
- Ferguson, Clare E; Lambell, Kate J; Ridley, Emma J; Goh, Gerard S; Hodgson, Carol L, Holland, Anne E; Harrold, Meg; Chan, Terry; Tipping, Claire J. Muscularity of older trauma patients at intensive care unit admission, association with functional outcomes, and relationship with frailty: A retrospective observational study. Australian Critical Care. 2024.
- Holland, Anne E; Dowman, Leona. Using change in 6-minute walk distance to predict survival in progressive pulmonary fibrosis: A promising measure in need of precision Respirology. 2024.
- Cox, Narelle S, Bondarenko, Janet; Chong, Melissa; Marceu, Tunya; Perryman, Jaycie; Holland, Anne E. Rapid real-world implementation of pulmonary telerehabilitation: good fortune or COVID-19 luck? ERJ Open Research. 2024.
- Jones, Arwel W, King, Bill E, Cumella, Andrew; Hopkinson, Nicholas S, Hurst, John R, Holland, Anne E. Use of infection control measures in people with chronic lung disease: mixed methods study. ERJ Open Research. 2024.
- Upham, John; Le Lievre, Chantal; Jackson, David; Masoli, Matthew; Wechsler, Michael; Price, David Defining a severe asthma super-responder: findings from a Delphi process. 2024.

- Nayia Petousi; Ian D Pavord; Brian Daniel Kent. Type-2 inflammation: a key treatable trait associated with lung function decline in chronic airways disease. Thorax. 2024.
- Jian Luo, Yi-Ling Chen, Wentao Chen, et al. Pre-existing asthma as a comorbidity does not modify cytokine responses and severity of COVID-19. Authorea. 2024.

Our partners

Contacts

If you would like to contact us, please reach out at:

www.treatabletraits.org.au

treatabletraits@newcastle.edu.au

https://www.linkedin.com/company/cre-treatable-traits/